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General 
Introduction and 
Scope of the Thesis 
"The greatly compressed bodies of the vertebrae ... 
Were so soft they could easily be cut with a knife. " 
Harvey Cushing, 1932 
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GENERAL INTRODUCTION 
Harvey Cushing already described in 1932 the skeletal phenotype of patients with 
endogenous hypercortisolism. He reported a tendency to become round-shouldered 
(kyphotic) even to the point of measurable height loss associated with lumbo-spinal pain 
[1]. His description is nowadays recognised as the typical clinical presentation of a 
patient with an osteoporotic stature and vertebral fractures. After the introduction of glu-
cocorticoids in the treatment of a wide variety of diseases, also the association of osteo-
porosis with exogenous hypercortisolism was recognised [2]. It became the most fre-
quent form of secondary osteoporosis [3]. Osteoporosis due to glucocorticoids seems to 
be dose dependent. It has to be emphasised that also the disorders for which these agents 
are given may themselves cause bone loss. The overall incidence of osteoporosis in 
patients taking glucocorticoids for more than six months approaches 50% [4, 5]. 
For over fifty years we now recognise the relation between glucocorticoid use and osteo-
porosis but only recently more data become available about the prevalence of glucocorti-
coid use and the relation between dosage and incidence of fracture. In the United King-
dom (UK) the prevalence of the long-term use of systemic glucocorticoids was studied 
recently by Walsh et al. He found that 0,5% of the Nottinghamshire population was tak-
ing long-term glucocorticosteroids [6]. Exact data on the chronic use of glucocorticoids 
in the Netherlands are not available, but it had been suggested that around 75000 patients 
are treated with corticosteroids [7]. 
If fracture occurs the patient will come under medical attention and only than the possi-
bility of steroid-induced osteoporotic fracture will be taken into account. Thirty to thirty-
five percent of patients receiving long-term glucocorticoid therapy have vertebral frac-
tures, and the risk of hip fracture is 50% higher in these patients compared to that in age-
matched controls [5]. Others reported 2- to 3-fold higher incidence of bone fractures in 
glucocorticoid treated patients with ranging from 8-18% [8-10]. From recent data pub-
lished on the steroid dose and fracture risk in the UK, it appeared that already an average 
daily dose of 2,5 mg of prednisolone per day could increase the risk of non-vertebral 
16 --- PART ONE 
fracture risk with 17%. In doses between 2,5 mg and 7,5 mg this risk was 36% and in 
average daily dose over 7,5 mg it was increased with 64% [11]. 
The cost of treatment of osteoporotic fractures is high and the consequences for the 
patients are multiple. Therefore there is a clear need for strategies to stratify the risk for 
osteoporotic fractures. At present Bone Mineral Density (BMD) measurements with 
Dual X-ray Absorptiometry (DXA), provide an accurate and precise way, although it 
remains questionable whether the relation between BMD and fracture risk is similar in 
glucocorticoid treated patients compared to what is found in postmenopausal women. In 
postmenopausal women, a decrease of 1 Standard Deviation (SD) or about 12% in BMD, 
is associated with a doubling of fracture risk [12-15]. This relationship may be an under-
estimate in patients treated with glucocorticoids, who appear to suffer fractures at BMD 
values higher than in postmenopausal osteoporosis [16]. 
The identification of patients at risk, the development of prevention and treatment strate-
gies, together with the creation of higher awareness of the medical profession on the risk 
of steroid induced osteoporosis are the challenges for the near future. 
SCOPE OF THE THESIS 
Glucocorticoid-induced osteoporosis is a serious disease that strikes millions of people 
world-wide every year. Nevertheless much debate is still going on about the preferred 
strategies to be followed and the magnitude of the problem. Therefore, the first aim of 
this thesis was to review the current strategies to identify the patient at risk and the 
options available for prevention and treatment of this serious skeletal disease. In addition 
we tried to obtain insight in the magnitude of the population at risk in The Netherlands. 
We also studied the effects of inhaled glucocorticoids on bone mineral density and mark-
ers of bone turnover. 
The second aim was focused on the prevention and treatment of glucocorticoid-induced 
osteoporosis. First of all the acute effect of etidronate on markers of bone turnover was 
studied in glucocorticoid treated patients. Subsequently, in two separate studies the 
effects of etidronate in the prevention and treatment of glucocorticoid-induced osteo-
porosis was investigated. 


Update on 
the Pathogenesis and Treatment of 
Glucocorticoid -Induced Osteoporosis 
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CHAPTER 1 
GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
1.1. DEFINITION 
The currently accepted definition of osteoporosis is, a systemic skeletal disease charac-
terised by low bone mass and micro-architectural deterioration of bone tissue, with a 
consequent increase in bone fragility and susceptibility to fractures [17]. BMD can be 
measured with acceptable accuracy and precision and forms the basis for an operational 
definition of osteoporosis with better clinical utility [18]. A working group of the W orId 
Health Organisation (WHO) has proposed guidelines for the interpretation of bone mass 
measurement in Caucasian woman. Four categories are discriminated, based on measure-
ment of BMD and the presence or absence of osteoporotic fractures. The BMD of the 
individual is compared to the average mean of young healthy individuals and expressed 
in standard deviation (SD) below the mean [19]. 
Those categories are: Normal bone mass 
·BMD with aT-score> - 1 SD 
Low bone mass or osteopenia 
·BMD with aT-score < -1 SD and:2: -2.5 SD 
Osteoporosis 
·BMD with aT-score < -2.5 SD 
Established osteoporosis 
·BMD with aT-score < -2.5 SD and the presence of fractures 
A potential restriction of the WHO classification is, that it has been developed in an 
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Figure 1.2.1 Effects of glucocorticoids on different target organs. 
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attempt to describe the severity of the disease for women with post-menopausal osteo-
porosis and may not be accurate for corticosteroid-induced osteoporosis [16,20]. How-
ever to establish an international standard, the WHO cliteria are also used in corticosteroid-
induced osteoporosis. Two groups have launched guidelines for corticosteroid induced 
osteoporosis [21,22]. Recently the UK consensus group updated their guideline [23]. We 
will discuss these guidelines in paragraph 4.2. 
1.2. PATHOPHYSIOLOGY 
Corticosteroids can affect bone directly, by altering calcium and bone metabolism, but 
also indirectly by altering different hormonal axes and protein metabolism [24-30]. (Fig-
ure 1.2.1) 
1.2.1 Effects of glucocorticoids ou the skeletou 
1.2.1.1 Cellularlevel 
Glucocorticoids exert their action on bone on many different levels. The precursors of 
osteoblasts are multipotent mesenchymal stem cells, while the precursors of osteoclasts 
are hematopoietic cells of the monocyte Imacrophage lineage. The development of both 
osteoblasts and osteoclasts is controlled by growth factors and cytokines that are pro-
duced in the bone marrow microenvironment and is modulated by systemic hormones 
and probably by mechanical signals [31]. At the cellular level corticosteroids decrease 
the number of osteoblast precursor cells by about 86% and also shorten their lifetime 
[32]. Osteoblasts in different stages of differentiation have different responses to gluco-
corticoids, mediated through their glucocorticoid receptor [33]. The use of glucocorti-
coids results in increased differentiation of osteoblast precursors and thereby causes 
lower rates of proliferation and protein synthesis [34-40]. Glucocorticoids also affect 
several growth factors secreted by bone cells. The synthesis of insulin-like growth fac-
tors (IGFI) is inhibited and glucocorticoids increase the production of binding proteins 
that can trap IGF I. IGFs have opposite effects to glucocorticoids, since IGFs increase 
bone cell replication and bone formation. Therefore the inhibitory effects of glucocorti-
coids on the IGFaxis are to an extent responsible for the inhibitory effects of these 
steroids on bone formation [41-43]. 
Decreased synthesis of matrix proteins like type I collagen [44] and osteocalcin [45] by 
the osteoblast, is a result of decreased gene transcription and decreased m-RNA stability 
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due to glucocorticoids. Not only type I collagen and osteocalcin but also osteopontin, 
fibronectin, B 1 Integrin, bone sialoprotein and insulin like growth factor are modulated 
by glucocorticoids [46]. The inhibition of integrin expression in osteoblasts impairs their 
attachment to bone [47]. 
Another effect of glucocorticoids is the increased expression of PTH receptors on the 
osteoblast. 
The response of bone cells and bone organ cultures to glucocorticoids depends on the 
timing and possibly the glucocorticoid dose. Gallagher demonstrated that low dose of 
glucocorticoids and short incubation periods stimulated both cell growth and collagen 
synthesis in human osteoblast cells [48]. In contrast a long-term culture with supraphysi-
ological doses of glucocorticoids inhibited cell growth and collagen synthesis [49]. 
In contrast to osteoblasts, the osteoclastic response to glucocorticoids is indirectly medi-
ated. Also reduction of osteoclast precursor cells and decrease of lifetime of the osteo-
clast has been reported [50]. 
1.2.1.2 Tissue level 
In contrast to linear or appositional bone growth, skeletal turnover in adults occurs 
through quantitative changes in discrete bone remodelling sites called basic multi-cellu-
lar units (BMU's) or bone remodelling units (BRU's) [51-54]. This theory is now widely 
accepted, and the major events in the bone remodelling cycle have been defined as acti-
vation --+ resorption -> reversal --+ formation --+ quiescence [51,55-57]. Normal bone 
turnover is characterised through the tight coupling of bone resorption and formation. 
However the use of glucocorticoids results in uncoupling of bone remodelling by acting 
in two discrete ways: 1) through direct action on the osteoblast, and 2) through increased 
bone resorption caused by indirect modulation of calciotropic hormones, cytokines, and 
prostaglandins [50]. 
Glucocorticoid-induced bone loss can be explained by the fact that the amount of new 
bone synthesised is less than that removed by osteoclast [58-62]. To this net negative 
effect contributes a decrease in the period of active bone formation [59]. Imbalance at the 
level of the BMU appears to be largely driven by the decrease in bone formation. Never-
theless there is also an increase in resorption although this seems to be more explicit in 
the early phase of glucocorticoid use [58-62]. Furthermore, the positive effect of gluco-
corticoids on the number of activated BMU's leads to an increased number of resorption 
areas in different stages of resorption and formation. This results in a progressive thin-
ning of the trabeculae [58]. 
It has been shown, that later on the resorptive cavities no longer contain osteoclasts so 
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that it seems more a problem of the osteoblasts, which are too slow to fill the resorptive 
cavities. Thus, it is likely that the effects of glucocorticoids on bone formation are much 
more dramatic than their effects of glucocorticoids on bone resorption. This is consistent 
with the histological picture of glucocorticoid-induced osteoporosis, which consists of 
thinned rather than perforated trabeculae, whereas in idiopathic osteoporosis perforation 
appears to be more prominent [58]. 
1.2.2 Effects of glucocorticoids ou calcium and phosphate homeostasis. 
Normal calcium homeostasis and the effects of glucocorticoids are shown in figure 1.2.2. 
Two mechanisms of intestinal calcium absorption have been identified. The active trans-
port is an energy dependent process and occurs against an intestinal calcium concentra-
. Absorption Ca 
--+ 5mmol 
+? ,-------, 
+- Secretion Ca 
5mmol 
Calcium 
Formation Ca 
lOmmol 
Resorption Ca 
lOmmol 
Bone (total Skeleton) Ca 
25 mmol 
Figure 1.2.2 The interaction of glucocorticoids with the overall calcium homeostasis. 
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tion gradient. This system is already saturated by a low concentration of intestinal calci-
um and is vitamin D dependent [63]. The second mechanism is passive diffusion of cal-
cium across the intestinal wall. 
In most but not all studies, use of glucocorticoids is associated with a decreased intestinal 
absorption of calcium and phosphate [64-66]. Two studies reported normal calcium 
absorption in patients taking glucocorticoids, except in those with fractures [67,68] and 
another study even reported an increase in fractional calcium absorption in patients treat-
ed with corticosteroids compared to that in controls [69]. If intestinal calcium absorption 
decreases, it occurs early in the first weeks of glucocorticoid therapy and is partially dose 
dependent [70,71]. In glucocorticoid excess primarily the active intestinal calcium 
absorption is inhibited [72-75]. However, treatment with pharmacological doses of 1,25-
dihydroxyvitamin D3, can only partially reverse intestinal calcium loss [69]. Other stud-
ies showed that the impairment of intestinal calcium absorption appears also to be inde-
pendent of vitamin D metabolism [64,71,76,77]. Therefore lowered fractional intestinal 
calcium absorption in corticosteroid treated patients can only be partially explained by 
lowered active calcium absorption. So other unknown effects of glucocorticoids on 
intestinal calcium absorption must be present. Inhibition of protein synthesis, especially 
decreased synthesis of vitamin D binding protein [8,25,78] and decreased calcium 
release from mitochondria because of depletion of mitochondria adenosine triphosphate 
[79] are suggested as potential mechanisms. 
As passive diffusion of calcium across the intestinal wall is not altered in the presence of 
corticosteroid excess, it becomes the major pathway for calcium absorption. Therefore 
the overall reduction in fractional calcium absorption is even more severe when dietary 
calcium is restricted [80]. Thus high doses of calcium should be given to patients using 
glucocorticoids. 
Another reason for calcium supplementation is the altered renal handling of calcium and 
phosphate in patients treated with glucocorticoids. Sustained glucocorticoid excess 
results in increased GFR, marked hypercalciuria, and a doubling of fasting urine calcium 
excretion [70,81-84]. This has been a consistent finding in different studies and is proba-
bly mediated by a direct inhibitory effect of glucocorticoids on renal tubular calcium 
reabsorption that occurs in spite of elevated levels of PTH and increased sodium excre-
tion [76,82,84,85]. Phosphaturia and decreased tubular reabsorption of phosphate also 
have been reported [86-89]. 
Decreased intestinal calcium absorption and increased renal excretion of calcium will 
lead to a negative calcium balance and thereby to secondary hyperparathyroidism with 
increased bone turnover and subsequently increased bone resorption [66,76,82,90]. 
Furthermore increased bone resorption and decreased bone formation, caused by the 
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combination of glucocorticoids and secondary hyperparathyroidism, will lead to an 
increased filtered load of calcium and contributes to a greater renal calcium loss. 
1.2.3 Effects of glucocorticoids on vitamin D and PTH homeostasis 
The possible contribution of alterations in vitamin D metabolism with steroid-induced 
osteoporosis has been extensively studied but the results seem to be inconclusive. Low 
[64,91] and normal [76,92] levels of 25-(OH)D3 have been found in corticosteroid treat-
ed patients. Circulating levels of the active metabolite 1,25-(OHh D3 have also been 
shown to be low [91], normal [77,92], or increased [71,75] in corticosteroid treated 
patients. This can be partly explained by short and long-term effects of glucocorticoids 
on vitamin D metabolism: on the short-term 1,25-(OHh D3 levels were increased, on the 
long-term 1,25-(OHh D3 and 25-(OH)D3 levels were normal. Seeman et al [77] reported 
no effects on normal levels, production and clearance rates of 1,25-(OHh D3 in patients 
before and during treatment with high doses of glucocorticoids or before and after suc-
cessful treatment of endogenous hypercortisolism. Low levels of 1,25-(OH)z D3 and 25-
(OH)D3 could be explained by other effects like, the underlying disease for which gluco-
corticoids have been prescribed, sunlight exposure, dietary factors and seasonal variation 
of vitamin D metabolites. From these data an absolute deficiency of active vitamin D 
does not seem likely to be of predominant pathofysiologic importance in glucocorticoid 
induced osteoporosis. 
The same problem returns when interpreting the studies on PTH in glucocorticoid treated 
patients. Elevated [66,76,93] and normal PTH values have been reported [35,77,86,94]. 
Elevated PTH levels are often found in patients on chronic glucocorticoid treatment. 
Increased secondary production of PTH, direct stimulation of parathyroid cell secretor 
activity, and increased osteoblast sensitivity to PTH are possible mechanisms by which 
glucocorticoids may modulate parathyroid activity and cause PTH mediated bone loss 
[84]. , When secondary hyperparathyroidism is present, administration of calcium sup-
plements and 25-(OH)D3 [76] can reverse it. It must be mentioned, that decreased calci-
um absorption, increased bone resorption and changes in circulating vitamin D and PTH 
are mainly observed in patients receiving the higher dosages of corticosteroids. 
1.2.4 The effects of glucocorticoids on sex hormones 
Glucocorticoids have a negative effect on the sex hormone status in men and women, 
which may in turn increase bone resorption (See figure 1.2.4). This is caused by 
decreased gonadal stimulation due to inhibition of pituitary gonadotrophin secretion. The 
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Figure 1.2.4 Effects glucocorticoids on pituitary and adrenal axes. 
secretion of luteneizing hormone (LH) in response to luteneizing hormone-releasing hor-
mone (LHRH) is reduced in both men and women [95,96]. Glucocorticoids also decrease 
follicle-stimulating hormone (FSH)-induced oestrogen production. Furthermore suppres-
sion of corticotrophin (ACTH) leads to adrenal atrophy and reduced production of adren-
al androgens [97]. 
Also direct negative effects of glucocorticoids on ovaries and testes have been reported 
[95,96]. Glucocorticoids decrease testosterone production in the testis [98,99]. Men 
receiving glucocorticoid drugs have a dose-related reduction in circulating testosterone 
concentrations of nearly 50% in comparison with controls [29,30,100-102]. The combi-
nation of glucocorticoids and oestrogen deficiency has potentiating effects on the rate of 
bone loss [103]. So postmenopausal women receiving corticosteroids are particularly 
susceptible to bone loss [104]. 
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1.2.5 Other factors that contribute to bone loss caused by glucocorticoids 
Other factors that contribute to bone loss caused by glucocorticoids are summarised in 
table 1.2.5. The underlying disease for which corticosteroids are prescribed and the co-
medication used may contribute to bone loss. Furthermore cytokines may playa modula-
tory role in this process, for example in rheumatoid arthritis. However, the contribution 
of these factors has only been marginally studied [104-109]. Chronic disease per se, with 
its decreased activity and mobility, also bears a risk for osteoporosis [110]. 
Miscellaneous factors in glucocorticoid bone loss 
Underlying disease 
Modulation by cytokines 
• Co-medication 
Myopathy 
Immobilisation 
Table 1.2.5 
In post-organ-transplantation patients the concomitant administration of immunosupres-
sants and glucocorticoids has negative effects on bone [108,109,111,112]. 
Glucocorticoids also have general catabolic effects. In muscle this is particularly impor-
tant, as shown in patients with Cushing's syndrome [113-115]. A striking association 
between the presence of steroid myopathy and osteoporosis has been demonstrated. The 
muscle weakness is not only due to glucocorticoid use, but also determined by underly-
ing conditions. In disease entities as rheumatoid arthritis or polymyositis, glucocorticoid 
-induced myopathy can hardly be distinguished from muscle weakness resulting from the 
disease process itself and subsequent inactivity [116]. Inactivity and muscle loss both 
lead to bone mineral loss [117]. All the factors involved in glucocorticoid induced bone 
loss are summarised in figure 1.2.5 (page 30). 
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CHAPTER 2 
SKELETAL AND NON-SKELETAL ASPECTS 
OF FRACTURE RISK 
2.l. FRACTURE RISK IN PATIENTS TREATED WITH GLUCOCORTICOIDS 
31 
There are no reliable epidemiological data concerning the prevalence and incidence of 
corticosteroid use, the average dose used and its relation to fractures. These data are 
essential for developing preventive and therapeutic strategies. Furthermore, the factors 
involved in fracture risk are complex and involve of both skeletal and non-skeletal fac-
tors, as shown in figure 2.1.1 (page 32). 
Observational data in patients with rheumatoid arthritis treated with glucocorticoids indi-
cate that the risk of hip and other non-vertebral fractures is doubled [9,10], while vel'te-
bral fracture prevalence may be increased four- to five-fold [118,119]. In prospective 
studies in transplanted patients treated with glucocorticoids, fractures have been reported 
in one-third of the patients [120,121]. The determinants of low bone mass in glucocorti-
coid treated patients, like underlying disease, altered vitamin D metabolism, co-medica-
tion etc., have been described in chapter 1. 
Obviously the risk of fracture is not only dependent on these factors, but also on the dose 
of glucocorticoids used. Higher doses of glucocorticoids result in higher fracture rates 
[11]. One cross-sectional and one retrospective study found a positive relation between 
cumulative dose of glucocorticoids and fracture risk [11,108]. Reid et al. suggested a 
positive conelation between cumulative glucocorticoid dose and low bone mineral densi-
ty [122]. This was confirmed in other studies [108,109,123-126]. A cumulative dose of 
10 grams of prednisone is associated with an increased risk of osteoporosis [127]. Only 
one study failed to demonstrate a relationship between bone density and the dose or 
32 
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Figure 2.1.1 Determinants of fracture risk and the effect of glucocorticoids. 
duration of glucocorticoid treatment [128]. 
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The minimal dose of glucocorticoids associated with rapid bone loss is not well estab-
lished. In general a daily dose of ~ 7,5 mg/day is defined as a harmful dose for the skele-
ton, however individual variability of susceptibility can lead to bone loss at lower 
dosages, as shown very recently by van Staa [129]. One of the determinants of fracture 
risk which can be measured and modified is bone mass. The severity of low bone mass is 
characterised by the use of BMD measurement, often expressed as a T-score. In the T-
score, both age and peak bone mass are weighted in a way that severity of (post-
menopausal) osteoporosis could be expressed. With respect to glucocorticoid-induced 
osteoporosis it is still questionable whether the T-score is appropriate to express and 
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define glucocorticoid-induced osteoporosis. Studies to support the use of the T-score in 
glucocorticoid-induced osteoporosis are still lacking. Furthermore it is not known 
whether the correlation between BMD and fracture risk, as shown in postmenopausal 
osteoporosis, is similar in steroid treated patients. Luengo et al. suggested, in their cross 
sectional study of patients taking glucocorticoids for asthma, that the BMD fracture 
threshold compared to age-matched osteoporotics not using glucocorticoids, lies at a 
higher level [16]. Peel et al. found a 6.2 fold increase in vertebral fracture in 76 post-
menopausal women with rheumatoid arthritis treated with glucocorticoids, although lum-
bar spine BMD was only decreased with < 1 SD [l30]. Recently Banffer et al [20] pre-
sented also evidence for a higher susceptibility for fractures in case of glucocorticoid 
use. It appeared that bone loss is related to daily dose, duration of therapy and cumula-
tive dose. 
In our opinion, the cumulative corticosteroid dose appears to be a major risk factor for 
bone loss and subsequent fractures. Especially young people and postmenopausal 
women, who take excess amounts of corticosteroids for long periods of time, are at risk 
for accelerated bone loss [3,127]. In addition, prospective studies are urgently needed to 
define the relationship between BMD and fracture risk at different maintenance dose of 
glucocorticoids. Meanwhile we have to be pragmatic and treat our patients as described 
in chapter 4. 
2.2 OTHER ASPECTS OF FRACTURE RISK 
2.2.1. Biochemical markers of bone turnover 
As described above, glucocorticoid induced bone loss results from a combination of 
inhibitory effects on bone formation and enhanced bone resorption, with the inhibitory 
effect on bone formation appearing to be the most important (See chapter 1). 
The rate of formation or degradation of bone matrix can be assessed either by measuring 
enzymatic activity of bone forming or resorbing cells- such as alkaline and tartrate resis-
tant acid phosphatase- or by measuring bone matrix components released into the circu-
lation during formation and resorption. These markers have been separated into forma-
tion and resorption markers (see table 2.2.1, page 34). However, it should be kept in 
mind that bone markers could not discriminate between turnover changes in cortical or 
trabecular bone and not reflect changes at the level of the individnal BMU. 
Furthermore circulating levels of these markers can be influenced by factors other than 
bone turnover, such as their metabolic clearance (liver uptake, renal excretion, and/or 
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Table 2.2.1 Markers of bone metabolism. 
FORMATION RESORPTION 
Serum I Plasma I 
.. Osteocalcin 
.. Total and bone specific alkaline 
phosphatase 
.. Pro collagen I carboxy-
.. Tartrate-resistant acid phosphatase 
.. Pyridinoline and pyridinoline containing 
peptides 
Terminal extension peptide (PITP) 
Urine I 
.. Urinary Pyridinoline and desoxypyridinoline 
(collagen cross-links) and containing peptides 
.. Fasting urinary calcium and hydroxyproline 
.. Urinary hydroxylysine glycosides 
trapping on bone hydroxyapatite). Thus, each of these assays needs to be validated in a 
specific clinical situation before conclusions about their clinical utility can be drawn 
[131]. 
Advantages of these markers are the general availability and their ability to detect acute 
changes in bone metabolism. Also the discomfort of the patient by collection of blood or 
urine is minimal. The immunoassays of osteocalcin and bone specific alkaline phos-
phatase represent so far the most effective markers of bone formation in osteoporosis. 
Measurement of pyridinium cross-links, and some of its related peptides, is an improve-
ment in the assessment of bone resorption. Well-characterised immunoassays are valu-
able alternatives to the HPLC technique of measuring crosslinks. 
The use of biochemical markers in the prediction of osteoporotic fractures has only been 
studied in postmenopausal women. From a number of epidemiological studies it appears 
that especially markers of bone resorption predict future fractures independent of BMD 
[132,133]. Paragraph 3.4 describes the effects of glucocorticoids on markers of bone 
metabolism. 
However additional studies are certainly needed to evaluate whether there markers are 
really helpful in a better stratification of the patient at risk Therefore the use of bone 
markers will improve assessing the risk of osteoporosis by BMD measurements. 
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2.2.2. Biomechanical aspects 
The biomechanical competance of bone is for 75-80% explained by bone mineral density 
as can be measured by densitometry [134]. The remainder is explained by the composi-
tion of bone mineral or matrix [135]. Based on this observation one might expect that a 
rise in BMD will always be related to a reduction in fracture risk. That this is not always 
the case, is shown by the observations obtained during fluoride treatment [136-138]. 
Although treatment with this drug induces a considerable rise in BMD, no clear reduc-
tion in fracture incidence is observed. The potential explanation for this phenomenon is 
that fluoride probably increased the crystallinity of bone mineral with a subsequent 
decrease in elasticity [136]. As a consequence the fragility of bone can even increase. 
This observation clearly indicates that increases in bone mass can only results in fracture 
reduction in a case a normal bone matrix is formed. It is clear that such changes can only 
be assessed by invasive techniques and not by for instance DXA measurement. Although 
commonly available densitometric techniques can not assess these changes, bone mass 
measurements provide an accurate indication of vertebral compressive strength as 
assessed in vitro [l39,140]. 
The amount of bone mineral can be measured in several ways. DXA is widely used 
nowadays. However, by using DXA only the areal density is measured (g/cm2). With the 
use of quantitative computer tomography (QCT-scan) bone is measured in a three-
dimensional way and consequently a volumetric density is obtained. Furthermore QCT 
offers the possibility to differentiate between trabecular and cortical bone. McBroom et 
al. found that removal of the vertebral cortex was associated with approximately 10% 
reduction in vertebral load to failure [141-146]. However QCT has the disadvantage of 
higher radiation exposure and the potential influence on the BMD measurement of 
changes in marrow fat, that for instance can occur during the use of glucocorticoids 
[147]. Recently Bolotin also demonstrated inaccuracies in DEXA measurements caused 
by body fat [148]. However, in general QCT predictions of local trabecular bone material 
properties appear not to be superior to those measured by DEXA [149]. 
Another factor which adds to the biochemical competance of bone is the spatial orienta-
tion of trabeculae, the so-called microarchitecture of bone. Currently experimental meth-
ods are available to obtain more insight in the microarchitecture of bone. It is possible to 
"measure" architecture by using the complete three-dimensional architectural structure of 
the trabecular bone measured by an advanced technology of three-dimensional micro 
computed tomography (micro-CT) scanning [150,151]. This can be used as a highly 
accurate and automated tool to measure precise changes in bone stereology, volume and 
projection, and micro-architecture in the evaluation of bone [152]. Unfortunately the 
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clinical implication of this technique is limited because miCl'o-CT and micro-FEA can 
only be used in cases where bone biopsies are available. 
The suggestion that microarchitecture is an important determinant of bone strength is 
also indirectly obtained from studies with inhibitors of bone resorption. The observed 
fracture reduction during treatment with this compounds appear not to be explained by 
the observed increase of BMD. Although definitive proof is lacking it has been suggest-
ed that the inhibition of bone resorption might decrease the chance that trabeculae are 
perforated, decreasing the loss of connectivity [153]. 
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CHAPTER 3 
INHALED GLUCOCORTICOIDS AND THEIR EFFECT 
ON BONE METABOLISM 
3.1. INTRODUCTION 
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The introduction of inhaled glucocorticoids some 20 years ago was a significant break-
through in the treatment of asthma limiting systemic side effects. 
Inhaled beclomethasone is widely used in daily dosages ranging from 1000 to 2000 /lg/d 
[154,155]. Data from the Prescription Pricing Authority in the UK show a 75% increase 
in prescriptions for inhaled and systemic glucocorticoids used in respiratory disease from 
1991 till 1994. Respiratory diseases are the most common indication for the prescription 
of corticosteroids both in hospital and general practice. In the general practice setting, 
there are 40 prescriptions of inhaled steroids for every prescription of orally administered 
corticosteroids [21]. Threshold inhaled doses for critical adverse events are not known, 
but these appear to be rare with established effective doses « 800 /lg/day in adults and < 
400 /lg/day in children) [156]. Nevertheless, it is clear that inhaled glucocorticoids can 
result in suppression of adrenal function [157,158]. This effect definitely occurs with 
doses of beclomethasone dipropionate of 2000 /lg/day [158], and doses of 3000 ~lg/day 
in case of budesonide [159,160]. Decreased circulating levels of osteocalcin [161-163] 
accompany suppression of cortisol production. High dose inhaled corticosteroids may 
have similar effects on bone density [164] and bone turnover as seen with orally admin-
istered corticosteroids [162,165]. Detrimental effects on bone metabolism, however, are 
assumed to be much lower with inhaled corticosteroids compared to oral corticosteroids, 
because of their high topical-to-systemic potencies and their metabolism by the liver 
[154]. 
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3.2. EFFECTS OF INHALED GLUCOCORTICOIDS ON 
ADRENOCORTICAL FUNCTION 
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The occurrence/extent of adrenal suppression is the most extensively studied systemic 
effect of inhaled corticosteroids. However, even if moderate and high doses of exoge-
nous corticosteroids affect the hypothalamic-pituitary-adrenal (HP A) axis, this rarely 
appears to be clinically important [166,167]. 
Nikolaizik showed a dose-dependent nocturnal cortisol suppression by inhaled budes-
onide of maximal 40%, given either as single evening dose of 400 pg or placebo or 400 
pg budesonide twice daily for 2 weeks in healthy persons. Such suppression of the HPA 
axis was seen after a single inhalation, and there was no evidence of a cumulative effect. 
The single-dose suppression was completely reversed one day later. The speed of recov-
ery after longer-term treatment could not be established in this study, as some suppres-
sion was still apparent 1 week after stopping therapy [168]. 
Apart from the HPA axis also significant suppression of adrenal androgens (androstene-
dione and dihydroepiandrosterone (DHEA)) has been described [169]. The clinical sig-
nificance of such systemic effects, especially in women, is not yet clear and needs to be 
elucidated in long-term follow-up studies in asthmatic patients. In general, dosages of 
beclomethasone of budesonide up to 800 pg/day are not accompanied by clinical impor-
tant suppression of the HP A axis. However, subtle adrenal suppression cannot be ruled 
out in dosages below 800 pg/day [170], because of different individual susceptibility and 
differences between inhaled corticosteroids and inhalation devices [171]. 
Furthermore most of the previous mentioned studies are biased by the use of the 250 pg 
corticotrophin-releasing test. Recent literature showed that the 1 pg corticotrophin test is 
more sensitive in discriminating suppression of the adrenal gland in users and non-users 
of inhaled glucocorticoids [172,173]. 
Finally, one has to be careful to extrapolate the effects of inhaled glucocorticoids on the 
HP A axis to their potential effects on other tissues like bone, skin and muscles [174]. 
3.3. EFFECTS OF INHALED GLUCOCORTICOIDS ON CALCIUM 
AND PHOSPHATE METABOLISM 
Studies on the effects of inhaled corticosteroids on calcium and phosphate homeostasis 
revealed conflicting results. In a cross-sectional study, Reid et al demonstrated that total 
body calcium was reduced in subjects receiving inhaled glucocorticoids in a dose of 400 
pg/day inhaled beclomethasone or 800 pg/day betamethasone [106]. Inhaled budesonide 
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3200 /lg/day causes alterations in the tubular reabsorption of calcium and phosphate 
although these changes were considerably smaller than those seen with systemic admin-
istration of glucocorticoids [175]. However, another study found increased levels of 
serum total and ionised calcium in postmenopausal women on 200-2000 /lg of inhaled 
beclomethasone daily [176]. 
In other studies no significant changes in intestinal calcium absorption, serum calcium, 
phosphate, and PTH have been documented with the use of high-dose inhaled steroids 
[67,161,169]. Toogood et al [169] showed that short term use of 600-2400 /lg/day budes-
onide did not influence calcium metabolism even in doses that significantly suppressed 
the function of the hypothalamic-pituitary-adrenal axis. Luengo [67] also could not find 
evidence for calcium malabsorption or hyperparathyroidism. 
Taken together, inhaled corticosteroids have minimal effects on the calcium and phos-
phate metabolism. The effects that have been described are dose related. The conflicting 
results in the different studies could be explained by possible confounding factors such 
as the different effects of several inhaled steroids, inhalation devices, previous systemic 
glucocorticoid use and the amount of medication absorbed in the oral-gastric-intestinal 
route. 
3.4 EFFECTS OF INHALED GLUCOCORTICOIDS ON MARKERS 
OF BONE METABOLISM 
Most authors stated that in contrast to oral steroids, inhaled steroids like beclomethasone 
and budesonide are considered to be free of adverse systemic side effects, if dosages 
below 1500 microgram are used [67,158,177]. Nevertheless, there is growing concern 
about the possible adverse effects of inhaled corticosteroids on bone. Studies about their 
effect on bone turnover, using biochemical indices, suggest that they may depress bone 
formation as evidenced by depressed serum osteocalcin [163,178] and increased bone 
resorption as shown by increased hydroxyproline levels [179]. 
When using bone markers to evaluate the effects of inhaled steroids, we have to keep in 
mind that not any isolated bone marker can be considered as a reliable guide to the extent 
of bone formation or resorption. Furthermore the relevance of some markers is not clear. 
Especially the older markers have problems regarding specificity. Therefore, it is impor-
tant to have specific immunoassays, to avoid errors, which lead to doubts about the rele-
vance of the used marker [165,177,180,181]. Conect handling of the serum samples is 
important because proteolytic enzymes in the serum will degrade some markers-like 
osteocalcin- to fragments. 
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Several studies have sought to evaluate the bone toxicity of inhaled glucocorticoids by 
using markers of bone metabolism (See table 3.4). All these studies showed a dose-
dependent decrease of serum osteocalcin with inhaled beclomethasone [182]. In healthy 
volunteer's, serum osteocalcin levels returued to baseline within one week after of dis-
continuation of the drug [183]. No clear changes were observed in the markers of bone 
resorption [176]. 
Jennings et a1. [161,162,184] were the only who evaluated the effect of inhaled budes-
onide, inhaled beclomethasone dipropionate and prednisolone on various indices of bone 
turnover in healthy volunteers. Serum osteoca1cin decreased after the use of budesonide 
in a daily dose of < 1200 flg. This effect occurred to an even greater extent with equiva-
lent doses of prednisolone and beclomethasone dipropionate. A dose of prednisolone of 
20 mg/day may be associated with a 50% reduction in osteocalcin levels [185], which is 
similar to the effect of high dose inhaled budesonide [162]. Unlike beclomethasone 
(2,500 ~lg/day) and prednisolone, budesonide (3,200 flg/day) did not affect serum alka-
line phosphatase [184]. 
Recent studies used the newer markers of bone formation and resorption, like PI CP 
(Procollagen type 1 C-terminal propeptide), type 1 carboxy terminal telopeptide (lCTP) 
and (deoxy)-pyridinoline crosslinks. A similar time-related suppression of bone forma-
tion, as in osteoca1cin, was observed using PI CP in the early phase after starting inhaled 
glucocorticoids [186]. 
In conclusion, several short-term studies in healthy non-asthmatic volunteers and asth-
matics taking high-dose inhaled steroids (> 1000 flg/day) have demonstrated changes in 
biochemical markers reflecting a decrease in bone formation (decreased osteoca1cin and 
PI CP) and occasionally an increase in bone resorption (increased hydroxyproline) 
[161,163,164,178]. Whether these effects remain after long-term use is unclear. How-
ever, the only long term study (2,5 years) available at present did not report changes in 
any of the biochemical markers of bone turnover [187]. The early changes in markers of 
bone turnover have been directly correlated with the frequency of administering cortico-
steroids and the total dose used [163,176,178,179,183,188,189]. When inhaled glucocor-
ticoids are used, changes in bone turnover markers were much less pronounced than in 
the case of oral steroids [169] and were more often seen with beclomethasone than with 
budesonide, when used at clinically comparable doses [163,189]. Similar dosages may 
vary in toxicity across individuals, since inter-individual variability has been demonstrat-
ed regarding the bronchial absorption of inhaled glucocorticoids [190]. Taken together, 
the early changes in biochemical markers of bone turnover appear to be related to the fre-
quency and the dose of inhaled glucocorticoid used. Therefore the first principle of treat-
ment remains the use of the lowest possible dose. 
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Ali No 
1991 [179] 8 disease Beclo 
Puolijoki 
1992 [176] 9 Asthma Beclo 
Kerstjens 70 Asthma Beclo 1994 [187] 
Declo = Beclomethasone 
Dudeso = Budesonide 
2000flgld 
20011 000/2000 
flg/d 
800flgld 
Not 4 weeks determined 
Each dose 
three weeks decreased 
osteocalcin 
and PICP 4 weeks and decreased in 2.5 years 
the acute 
phase 
PICP = carboxy terminal pro peptide of type I procollagen 
OHproline 
in urine 
elevated 
Not 
determined 
Initial 
transient 
elevated 
ICTP and 
urinary OH-
ICTP = cross-linked carboxy terminal telopeptide of type I collagen 
N = Number of participants 
41 
All 
postmenopausal 
women 
No effects on bone 
markers after 2.5 
years in this dose. 
Table 3.4 Effects of inhaled glucocorticoids on the markers of bone metabolism. 
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¢~;h~~; Method N Medication Cg~~~~1 B~D me~~red 
Reid Cross~ 400 "gld or 1986 [106) 
sectional 22 betamethasone Healthy QCT spine 
Wolff Cross- Beclornethasone Asthma on Radius, 
1991 [201) sectional 5 average dose systemicGC SPA spine and DPA Case control 326 ~gld treatment hip 
Packe Cross- Beclomethasone Mild Asthma 1992 [164) sectional 57 1000-2000"gld bronchus QCT Spine Case-control dilator alone 
Spine, 
Ip Beclomethasone and femoral 
1994 [202) Case-control 130 budesonide Healthy DXA neck, 
> 1000 "gld trochanter, 
ward's 
Spine, 
Herrala Prospective Beclomethasone femoral 1994 [203) longitudinal 19 1000 "gld Healthy DXA neck, clinical trail trochanter, 
ward's 
18 
Hanania Asthmatics Femoral 
1995 [204) Cross- '36 Beclomethasone or broncho- DXA neck, spine, 
sectional budesonide 800 "gld dilator 
therapy ward's 
-"Ion'o 
20 subjects on 17 
Packe budesonide 800 ~gld Astillnatic 
1996 [196) Cross- 40 20 subjects on never used QCT spine 
sectional beclomethasone inhaled or 
systemic 
1000 "gld ;teroids 
Luengo Beclomethasone and 
1997 [205) Case-control 48 blldesonide Mean Healthy DXA Spine 
dose 662 +/- 250 ~g/d 
10 
Struijs Prospective 12 Beclomethasone Asthmatics Spine, total 
33 800 ~gld broncho- hip, 1997 [195) longitudual II budesonide dilator DXA Femoral 
randomised 
800 "gld therapy neck,ward 
alone-
GC == Glucocorticoid; GE == Gastro-Enteral 
BMI== Body Mass Index; BMD == Bone Mineral Density 
QCT == Quantative Computer Tomography 
SPA == Single Photon Absorptiometry 
DP A == Dual Photon Absorptiometry 
DXA == Dual energy X-ray absoptiometry 
Table 3.5 The efffects of inhaled glucocorticoids on BMD. 
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~~~) Comments 
Decreased. 
Decreased only 
in the control 5 subjects in study and 
group not in 
jnhaled group. 
control group I 
Also compared high dose 
inhaled with intermittent 
Decreased. systemic GC, with high 
inhaled and continuous low 
dose systemic Gc. 
All sites Also a correlation between 
decreased BMI and higher average 
compared to daily dose. No differences 
control group in between women with or 
female not in without previous systemic 
male. use. 
Only postmenopausal 
No differences women. 
found. Careful instructions to 
minimise GE absorption 
One year follow up. 
Z-score femoral 
neck decrease. 
No differences 
on other sites. 
Decreased in The mean BMD in 7 
both groups patients in the budesonide 
using inhaled grouP. who never received 
steroids. oral GC, was approximately between control 
and withGC. 
No difference in No effect f system!c GC 
decrease of BMD use during the study on 
between groups. BMD. 
Decreased in all 
groups. Percent 
change from 
baseline in becla 
group significant. 
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3.5 EFFECTS OF INHALED GLUCOCORTICOIDS ON BONE 
MINERAL DENSITY 
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There are limited data available on the effects of inhaled glucocorticoids on bone mass. 
As outlined in chapter 1, other risk factors contribute to osteopenia apart from the dose 
of steroids (see figure 1.2.1) [193,194]. These risk factors may even be of greater rele-
vance when the total dose of steroids is not very high, as in the case of inhaled steroids. 
Moreover, severe asthma may in itself affect BMD through its effect on the lifestyle fac-
tors associated with BMD. Therefore, it is difficult to prove a direct link between the use 
of inhaled glucocorticoids and BMD. Most studies compare BMD of asthmatic patients 
treated with inhaled corticosteroids with BMD of healthy adults. This may lead to false 
conclusions about cause-effect relationships, since it is not known how BMD values 
would appear in non-steroid-treated asthmatic patients with similar disease severity. 
Another problem is that the assessment of the effects of inhaled corticosteroids on bone 
has often been complicated by the fact, that many patients have previously received 
short- or long-term treatment with oral corticosteroids, which are likely to have had 
effects on bone turnover. 
The studies conducted are summarised in the table 3.5. All studies were done in patients 
with asthma. The results are difficult to interpret, because different methodologies were 
used to assess bone mass and differences in past and current use of oral corticosteroids 
(including mixed oral and inhaled glucocorticoid use). Furthermore other factors like, 
insufficient numbers of subjects, differences in gender and menopausal status, different 
delivery systems and the use of too low doses for a too short period of time to expect 
changes, are involved. In our own study we found a minor decrease of bone mass after 
one year [195] (See chapter 6). Long-term, controlled studies are needed to clarify the 
effects of inhaled corticosteroids on bone metabolism and to assess the effects of poten-
tial confounding factors such as age, gender, menopausal status, choice of drug, delivery 
system [171], dosing schedule and duration of therapy. 
Also longitudinal studies of bone metabolism and BMD in patients with mild asthma 
starting inhaled budesonide or beclomethasone therapy are needed to show whether any 
initial changes already occur before systemic corticosteroid therapy is given [196]. 
It must be emphasised that the risk of osteoporosis should not defer clinicians from their 
prescription of inhaled glucocorticoids when indicated. However, recognition of their 
potential side effects on the skeleton is important. Therefore the lowest possible dose 
should be prescribed and BMD should be measured in patients at risk. 
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3.6 FUTURE EXPECTATIONS ON NEWER INHALED GLUCOCORTICOIDS 
AND THEIR EFFECT ON BONE MASS 
Some studies suggested that the newer inhaled corticosteroid fluticasone propionate has a 
more beneficial ratio of clinical efficacy versus systemic effect [197]. Recent studies 
showed that in asthmatic patients treatment with 750 IJg/day fluticasone was as effica-
cious as with 1500 /lg/day of beclomethasone [198]. Serum markers of bone formation 
(osteoca\Cin and PICP) were affected by beclomethasone but not by fluticasone [199]. 
Recently Pauwels et al [200] suggested that changing existing therapy with inhaled corti-
costeroids (either beclomethasone or budesonide) to fluticasone in a halved dose, result-
ed in a significant recovery of bone density in the spine, femoral neck and Ward's trian-
gle. Extensive data in this respect, however, have to be awaited. 
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CHAPTER 4 
THERAPY FOR CORTICOSTEROID-INDUCED 
OSTEOPOROSIS 
4.1 INTRODUCTION 
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Although glucocorticoids have a wide variety of clinical applications, their use is accom-
panied by multiple and serious side effects [2], including glucocorticoid-induced osteo-
porosis which contributes to significant morbidity [3,8,118,119,128]. Until recently, 
scarce data were available about prevention and treatment strategies in relation to gluco-
corticoid-induced osteoporotic fractures. 
Its obvious that if a therapy is initiated with such a wide spectrum of side effects, as glu-
cocorticoids, one should be aware of the correct indication and the lowest possible dose 
of such therapy. However, it appears that in a majority of hospitalised patients in the 
United States, glucocorticoids are not entirely prescribed in accordance with professional 
standards based on literature [206]. 
It is generally accepted that supra-physiologic doses of glucocorticoids, especially in the 
first 3-6 months, provoke an accelerated bone loss followed by a lower rate of loss in the 
subsequent years [207-211]. Cessation of glucocorticoid therapy after one year results in 
recovery of the BMD [209]. Therefore timing of initiating or cessation of therapy in glu-
cocorticoid-induced osteoporosis remains difficult and needs further study. Data from 
van Staa showed that after two months of starting glucocorticoids, even in a dose as low 
as 2,5 mg/day, an increase in fracture occurs. These data has to be further analysed to 
find out the underlying mechanism, including non-glucocorticoid related factors [129]. 
The most prominent pathophysiologic mechanism in glucocorticoid-induced osteoporo-
sis is the uncoupling of bone resorption and formation (Chapter 1). Unfortunately there is 
no safe and effective therapy yet, stimulating bone formation. There are only a few 
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prospective studies concerning bone loss and its prevention in patients starting glucocor-
ticoid therapy [208,212-214]. Only three, large prospective, placebo controlled ran-
domised clinical trails, has been performed focussing on the prevention and intervention 
of steroid-induced osteoporotic fractures. All used bisphosphonates, which are, classified 
as anti-resorptive agents [215-217]. The ideal treatment might be an anti-resorptive agent 
in combination with a stimulator of bone formation [218]. 
4.2. WHO AND WHEN TO TREAT 
The ideal strategy in the prevention and treatment of glucocorticoid-induced osteoporosis 
would be intervention before bone loss and concomitant fractures occur. Such an 
approach might result in a better quality of life for the individual patient and a potential 
reduction of costs in medical and social care. The targets of different therapies are 
showed in figure 4.2.1 however the main problem is how to identify the patients at high-
est risk. Bone mass measurements figure prominently in guidelines about glucocorticoid-
~ Calcium 
vitamin D 
COCORTICOIDS III------'~ -l- Sexhormones 
~ Thiazides ~ Estrogen Progestins 
Testosterone 
Anabolicsteroids 
Figure 4.2.1 Treatment options 
~ Bisphosphonates 
Calcitonin 
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induced osteoporosis [22,23], however, no prospective data have been obtained indicat-
ing that they predict osteoporotic fractures in corticosteroid-induced osteoporosis. Also, 
the BMD threshold of increased risk of fracture is unclear (See chapter 2). There is some 
evidence that the BMD threshold is higher in patients with vertebral fractures receiving 
corticosteroids, compared to those with postmenopausal fractures [16,20,130). 
Different cut-off points have been suggested with T scores from -1.0 to -1.5 SD [21-
23,218,219]. Eastell's group [23] in their updated review suggests that drug intervention 
will be targeted at those patients, both men and women, whose BMD is ~ 1 SD below 
the age-matched mean (Z-score) at spine or hip, or a T-score of -1.5 SD at these sites. 
They also suggested immediate intervention in those patients who received more than 15 
mg prednisolone or equivalent daily. The American College of Rheumatologists suggests 
intervention when T-score is:S; -1 SD. They also suggest calcium and vitamin D supple-
mentation when initiating glucocorticoid treatment. 
In non-steroid-treated patients, a previous history of low trauma fracture is a major risk 
for future fractures, irrespective of bone density. This is likely also to be the case in 
steroid treated patients, as previous fracture provides evidence that the skeleton has 
reached a point at which it is not able to withstand the stresses routinely placed upon it. 
Therefore patients with previous fractures should usually be offered preventive treatment 
against further bone loss, irrespective of their BMD. In my opinion the flow-chart from 
Eastell [23] with some modifications (Figure 4.2.2, page 48) is a useful tool in general 
practice. 
4.3. ALTERNATIVES IN DOSING SCHEDULE AND THE USE 
OF NEWER GLUCOCORTICOIDS 
Bone loss in corticosteroid treated patients is dose-related; therefore it is clear one has to 
prescribe the lowest effective dose to achieve minimum glucocorticoid exposure. Alter-
nate day therapy preserves normal function of the pituitary-adrenal axis, however it does 
not prevent bone loss [220-222]. Best therapy is to stop the glucocorticoid treatment. 
What will happen to bone mass after stopping corticosteroid therapy? Data on this issue 
are scarce. Recovery of bone mass after cessation of corticosteroid treatment has been 
described by Rizzato et al and Laan et al [209,223]. However, Laan's study showed that 
more than 25% had to restart prednisone treatment. Physicians are to optimistic about the 
duration of treatment with glucocorticoids [224]. Hall et al. [225], performed a study in 
postmenopausal women with rheumatoid arthritis, 119 patients without previous pred-
nisone treatment, 35 previously on prednisone therapy and 41 patients stilI on pred-
48 
Diagnostic work up: 
ESR, Serum Alk.Phos., Ca, 
TSH, Full blood count, 
Protein electrophoresis 
• Total testosterone in men 
Prolactin on indication 
1. Bisphosphonates 
2. Treat hypogonadism: 
-Testosterone in men 
- Oestradiol in premeno-
pausal women 
3. Calcitriol 
4. HRT, if appropriate, in 
postmenopausal women 
Assess BMD at the lumbar 
spine and hip at 1 year and 
then every 1-3 years 
dependent on the results 
General measures / choice of 
Corticosteroid regime :-: 7.5 mg 
/day for six months or more 
BMD T score <-1.5 
Z-score <-1 
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Glucocortioid dose 2 15 mg /day 
Or 
Age over 65 
If bone loss> 3 % at spine or 
7% at hip after 1 year start or 
change therapy. 
Refer to specialist if already 
on therapy 
Figure 4.2.2 Prevention and management of glucocorticoid induced osteoporosis. 
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nisone. He compared them with healthy controls. It was remarkable that no differences in 
BMD were demonstrated between the groups except those still on glucocorticoids. How-
ever a bias is suggested because patients with RA are known to have a lower bone mass 
as healthy individuals. 
The use of newer glucocorticoids, such as deflazacort, could have less toxic effects on 
bone. Studies showed that it has less inhibitory effect on calcium absorption and pro-
duces less bone loss compared to prednisone while maintaining its anti-inflammatory 
effects [93,226-228]. The crucial question, about which uncertainty remains, is the rela-
tive glucocorticoid potency of deflazacort [229-235]. It has been suggested that deflaza-
cort has a significantly lower milligram potency than prednisone and is consequently 
being used in non-equivalent doses in the comparative studies. 
4.4 CALCIUM AND VITAMIN D PREPARATIONS 
There is an ongoing discussion about the supplementation of calcium and vitamin D in 
corticosteroid treated patients. From a pathophysiological point of view, calcium and to a 
lesser extent vitamin D supplementation are logical therapeutic strategies. Unfortunately 
the scarce clinical studies on the effect of calcium and/or vitamin D on bone mass in glu-
cocorticoid treated patients are inconclusive [25,76,236-240]. Only calcitriol has been 
shown to be effective in the prevention of ClOP in patients starting glucocorticoid treat-
ment [208]. 
It appeared that calcium and vitamin D are essential in bone metabolism and that defi-
ciency of one of them leads to a decreased efficacy of other medication used in glucocor-
ticoid-induced osteoporosis. In a clinical trial Mulder et al [241] showed that reduction in 
serum calcium and vitamin D result in a diminished effect of etidronate given to 
osteopenic postmenopausal women. Therefore basal serum calcium and vitamin D levels 
should be measured in patients using glucocorticoids, and eventually supplemented. Cal-
cium intake of patients starting glucocorticoid treatment should be at least 1000-1500 mg 
a day. 
400 ill/day of vitamin D is recommended for the average patient in whom there is no 
reason to suspect vitamin D deficiency. In those patients who may be at risk for vitamin 
D deficiency (malabsorption and/or low diet vitamin D), serum level of 25-hydroxyvita-
min D should be measured. 
The use of thiazide diuretics and sodium restriction has been shown to reduce calcium 
excretion [82,242,243]. However, these data must be interpreted with caution because no 
randomised controlled trial has been published in glucocorticoid treated patients. Fur-
50 CHAPTER FOUR 
thermore, thiazide diuretics may aggravate the loss of potassium in corticosteroid treated 
patients. Hypercalcemia may develop in patients treated with a combination of vitamin D 
and thiazides. Therefore serum calcium levels should be monitored [244]. 
4.5 CALCITONIN 
Calcitonin is not registered for glucocorticoid-induced osteoporosis in the Netherlands. 
However, it is an inhibitor of bone resorption and some studies also suggest that it stimu-
late osteoblasts [245] and promotes enteral calcium absorption [246]. As its effect match 
the pathogenic factors involved in steroid induced osteoporosis, and suppression of 
endogenous calcitonin secretion has been described during glucocorticoid therapy [247, 
248], on first site it seems a rational therapy. However, studies performed with calcitonin 
are conflicting. This is due to insufficient sample size, heterogeneity of study popula-
tions, retrospective designs [214], poor steroid dose control [249], different routes of 
administration and reliance on short term changes in surrogate measures of osteoporosis 
[250]. The mentioned positive effect on calcium absorption is an indirect effect, pertinent 
to all anti-resorptive drugs. They all decrease serum calcium by decreasing the efflux of 
calcium from the skeleton (see chapter 1). The results of the three randomised-controlled 
trials published [208,251,252], are conflicting. Healy et al. [252] and Sambrook et al. 
[208] found no beneficial effect, Adachi et al. [251] however, reported a significant 
increase in bone mass after one year of therapy. This may be due to differences in patient 
populations; timing and dose of steroids used, and differences in co-treatment with calci-
um and vitamin D in the study and control groups. Overall, in the first year, calcitonin 
treatment seems to have a positive effect on bone mass in prevention and treatment of 
osteoporosis. After one year the effects are similar to those in the control group treated 
with calcium and vitamin D. A useful property of calcitonin is its analgesic effect in the 
acute phase of vertebral fracture [253]. However, for this purpose cheaper alternatives 
are available. The lack of proven efficacy on BMD and fracture reduction is the major 
disadvantage and does not support the use of calcitonin in daily clinical practice. 
4.6. SEX HORMONE REPLACEMENT 
Unlike the effect on BMD in postmenopausal osteoporosis, data on the effect of hormon-
al replacement therapy on BMD in glucocorticoid-induced osteoporosis are very limited. 
Furthermore no fracture studies has been published. It is believed that in premenopausal 
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regularly menstruating women, HRT has no place. Nevertheless the use of oestrogen 
replacement in oestrogen-deficient women who are receiving high doses of cortico-
steroids has been recommended, as long as its use is compatible with other medical con-
ditions of the patients [21-23]. 
Different mechanisms of actions by which HRT acts in ClOP have been described. First 
of all HRT results in inhibition of bone resorption. Furthermore, Greenberg et al. sug-
gested that 17 beta-estradiol (E2) and progesterone stimulate calcitonin secretion by 
rapid, direct and specific effects on thyroid C cells in rats. Therefore, gonadal hormones 
might have an additional effect in inhibiting bone resorption through a direct effect on 
calcitonin secretion [254]. An overview of studies with HRT in glucocorticoid induced 
osteoporosis is provided in table 4.6.1 (page 52). In one of the few studies of HRT in 
female RA patients using steroids [255], a small subgroup of 4 steroid treated patients 
was taking estrogens alone (Estraderm® 50), because of hysterectomy. It appeared that 
these patients lost significantly more bone than the remaining patients who took com-
bined HRT consisting of transdermal estradiol 50 f.lg daily with oral norethisterone. The 
recognised competition for osteoblast glucocorticoid receptors [33] and the positive 
results of a trial with progesterone in steroid-induced osteopenia [256,257], suggest that 
progesterone may be a more important component in HRT when it is used to treat 
patients who have received long-term glucocorticoid treatment. Further research on the 
effects of HRT on BMD and fracture risk, in glucocorticoid treated patients are necessarily, 
because the studies done were to small or not randomised. 
Taken together clear evidence for a beneficial effect of HRT in the treatment of gluco-
corticoid-induced osteoporosis is lacking. The use of HRT in ClOP should be limited to 
proven hypogonadism in pre-menopausal woman, and can be considered in the first 
years after menopause. 
In steroid treated men hypogonadism frequently occurs [29,102,258]. In the knowledge 
that hypogonadism per se accelerates bone loss [259-262], it seems reasonable to provide 
testosterone replacement to these individuals, even though data confirming this are very 
scarce. Reid reported, in a randomised crossover trial, that testosterone appeared to be 
effective as a therapy for low bone mass in 15 asthmatic men treated with glucocorti-
coids. Lumbar spine, but not hip BMD increased after one year of treatment. Also lean 
body mass increased. General guidelines, for the use of androgens in men, have been 
published recently [263]. 
Anabolic steroids have also been used in the treatment of glucocorticoid-induced osteo-
porosis. They have little place in the management of steroid induced osteoporosis in 
men, because they would reduce endogenous testosterone concentrations further. Their 
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IA;:/~:f Type study N I Follow- Study medication ResultsBMD Comments up 
Sub-aualysis Transdermal estradiol 50J.lg Hall Of steroid 24 daily with oral nor- Measured by DXA 200 postmenopausal 1994 
treated 21 months ethisterone 1 mg 12 days per Lumbar spine +3.5 % women with RA, on [255] 
subjects month or Estraderm 50 after Prox femur + 1.62 % chronic GC use. 
Studd Not Oestradiol 75 mg and Measured by DPA Postmenopausal wo-
1989 mentioned, 12 testosterone 100 mg Spine + 13.4 % men with asthma. probably months Longer than 5 years [266] percutaneous implant Hip +6.25% 5mg :aday 
8 patients receive 0.6256 mg Postmenopausal or 
Lukert 12 Premarin daily for 25 days One patient DXA amenorrheic women 1992 Retrospective 15 
months and 5 mg daily of And 7 patients DPA treated with predni-[213] "ww'd:~; 15-2~ on Spine+4.1% sone because of asthma 
Sam- Subanalysis Measured by DPA 38 postmenopausal brook 
of five 38 48 Different estrogen regimes Spine +0.7 % women with RA, 1992 months mean dose 6.2 mg / 
[2J>7] patients Hip non significant day 
Prospective 13 patients receive 200 mg Asthmatic men, mean Grecu 
randomised 12 medroxyprogesterone measured by QCT age 66, treated with 1990 23 acetate at 6 weeks intervals 
[256] controlled months and 1 gram of elemental Spine+17% 10-20 mg prednisone 
clinical trail 
calcium. a day, for over 1 year 
30 mg testosterone 
Reid Prospective Two propionate, 60mg Asthmatic men, mean 
1996 randomised times phenylprionate, 60 mg measured by DXA age 61, treated with 
[268] cross-over 12 isocaproate, 100 mg Lumbar spine +5.0 % 11.6 mg prednisone a 
clinical trail month decanoate, 250 mg/month day, during 8 years 
IMd~lJot_ 
Women, 1 pre-, 17 
Prospective 18 patients receive 50 mg postmenopausal Adami nandrolone decanoate every measured by DPA 
1991 randomised 35 18 3 weeks 1M and a diet with Distal forearm + treated with 10mg 
controlled months prednisone a day> 1 [264] 
clinical trail 1200 mg Ca and 600-800 IV 5.1% year because of 
vitamin D 
. diseases 
RA == Rheumatoid Arthritis; GC == Glucocorticoid; 1M = Intra-muscular; BMD = Bone 
Mineral Density; QCT = Quantatative Computer Tomography; DPA = Dual Photon 
Absorptiometry 
DXA = Dual enel'gy X-ray absoptiometry 
Table 4,6.1 Studies with sex-steroids in glucocorticoid-induced osteoporosis. 
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use in women is associated with beneficial effects on bone mass [264], but also with 
virilising side effects in 10-50% [264,265] of treated patients. The lack of controlled tri-
als with adequate measurements of BMD at appropriate places, the virilising potential 
and the adverse effect on the lipid profile, make these drugs not advisable for use in 
steroid induced osteoporosis. 
4.7 FLUORIDE 
Presently, sodium fluoride is the only registered stimulator of bone formation [269,270]. 
There are several studies suggesting a positive effect on spinal BMD in both the preven-
tion and treatment of steroid-induced osteoporosis [271-277]. Only the recent studies 
performed by Lems et al [271, 277] are randomised controlled prospective trials. Howev-
er in post-menopausal osteoporosis fluoride has been associated with deterioration of 
bone quality and increased fracture risk [138,278]. This effect appears to be dose depen-
dent as shown by others using lower dosages which resulted in a lower fracture incidence 
in postmenopausal osteoporosis [279,280]. So it appears that the therapeutic window for 
fluoride is small and its adverse effects are dependent on formulation and dosage. Slow 
release sodium fluoride appears to have no side effects when given intermittently [281]. 
In conclusion, the beneficial effects of fluoride on trabecular bone -the site of the greatest 
bone loss in corticosteroid treated patients- are counter-balanced by its intelference with 
normal mineralisation when present in high concentrations (see also paragraph 2.2.1). Its 
therapeutic window and anti-fracture ability in both post-menopausal and corticosteroid-
induced osteoporosis remain to be established. All together fluoride is not recommended 
as a first-line agent in steroid induced osteoporosis. 
4.8. BISPHOSPHONATES 
As earlier stated increased bone resorption induced by glucocorticoid use, could be coun-
teracted by anti-resorptive agents such as calcitonin, hormone replacement therapy or 
bisphosphonates. In this paragraph the use of bisphosphonates will be discussed. 
4.8.1 Possible mechanisms of action 
Bisphosphonates adsorb to bone mineral and inhibit bone resorption. Physico-chemical, 
intracellular and extracellular mechanisms are involved. Bisphosphonates act by being 
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Figure 4.8.1 Biochemical structure and biological activity of bisphosphonates. 
(With kind permission from RGG Russell) 
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selectively adsorbed to mineral surfaces in bone and then taken up by osteoclasts. There-
after they will interfere with recruitment, differentiation and resorptive activity of the 
osteoclast. The biochemical structure of a bisphosphonate comprises different parts with 
specific actions, see figure 4.8.1. [282] 
It is likely that bisphosphonates are internalised by osteoclasts, during the process of 
bone resorption. They interfere with specific biochemical cell processes in- and induced 
apoptosis of- the osteoclasts. Recently Luckman et al [283,284] published the two possi-
ble mechanisms by which different bisphosphonates works. Bisphosphonates that closely 
resemble pyrophosphate, like clodronate and etidronate, can be metabolically incorparat-
ed into nonhydrolysable analogues of ATP that may inhibit A TP-dependent intracellular 
enzymes. In nitrogen-containing bisphosphonates, such as alendronate and risedronate, 
the effects on osteoclast function are mediated by inhibition of different enzymes of the 
mevalonate pathway. Subsequently prenylation of different key regulatory proteins is 
inhibited which causes loss of osteoclast activity and induction of apoptosis. 
Bisphosphonates are considered as anti-resorptive compounds. In clinical studies it 
appeared that they are able to increase bone mass and reduce fracture rates. An explana-
tion of these findings could be, that in addition to the previous described actions on the 
osteoclasts, the ability of bisphosphonates to reduce the activation frequency and birth 
rates of new BMU's and the enhancement of the osteon mineralisation all contribute to 
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the increase of bone mass and the reduction of fracture rate. Another interesting possibil-
ity is that bisphosphonates decrease resorption less than formation at the individual BMU 
level and, therefore, increase bone balance at this site [285-291]. 
Also the suggestion that alencironate to some extent increases bone formation at the level of the 
BMU in ovariectomised baboons, is an interesting finding [292]. A similar effect has been sug-
gested in humans treated with clodronate [285,293]. Although certainly not conclusive, our 
own study described in chapter 10 could also SUppOlt an anabolic effect on the skeleton. 
Another possible mechanism of action of bisphosphonates is the immune modulating effects 
of bisphosphonates and the concomitant effect on the underlying disease. These are both 
factors that ar'e especially involved in glucocorticoid-induced bone loss [294,295]. 
Another interesting observation is that the rather limited increase of BMD in post-
menopausal patients with osteoporosis treated with bisphosphonates, substantially under-
estimates the fracture reduction demonstrated in clinical studies. It has been suggested 
that the observed reduction in fractures caused by bisphosphonates could only be 
explained for 30 to 50% by the increase of BMD. The additional effects of bisphospho-
nates on fracture reduction are not determined yet, but an additional effect of bisphos-
phonates on the quality of bone has been suggested [153,296]. 
4.8.2 Clinical experience with bisphosphonates 
Compared to postmenopausal osteoporosis, the studies on prevention and treatment of 
glucocorticoid-induced osteoporosis with bisphosphonates are scarce. Hornik and others 
recently did a database search, on controlled clinical trials concerning glucocorticoid-
induced osteoporosis [297]. They found 23 controlled studies [210-212,215,216,298-
315] assessing the treatment of ClOP. After selecting them for prospectiveness, mean dose 
of 7,5 mg prednisone / day or more, and adequate BMD measurements, 13 remained with 
842 participants (See table 4.8.1 and 4.8.2, page 56 and 57). The efficacy of bisphospho-
nates, measured as percent change in BMD over one year ranged from -10% to + 19% 
[212,303]. These results are heterogeneous; however, the studies dealt with heteroge-
neous patients with many different disease entities requiring glucocorticoids. The study 
of van Cleemput et al. [303], which is responsible for the 10% decrease in bone mass 
under bisphosphonate treatment was performed in a group of cardiac transplants with 
probably a vitamin D deficiency. As mentioned before bisphosphonates cannot act with-
out sufficient supply of calcium and vitamin D [241]. Furthermore the methods of mea-
suring bone mass were quite different in the different studies. The BMD data were col-
lected by QCT, DPA and DXA. The results obtained with these methods can not be com-
pared with each other. 
56 CHAPTER FOUR 
AuthorYr.l Study Control Follow Diseases N N ResultsBMD Comments 
Ref Design Medication Group treat plac vs. 
Rx (year) (control group) 
Mulder Cyclic I year Temporal Measured by DXA 
1994[210] P.R.C. Etidronate Nothing Arteritis 10 10 Spine + 1.4 %(- 5.0%) 
VanCleemput Cyclic Calcium Cardiac 
. Meas~r~~!2'{~7~~'" Set up as a comparison P.R.C 1 year Transplan~ 19 22 between two 1996[303] Etidronate D tation Fe~ Neck ~8.9%-(:;.60/0) treatments 
Adachi P.R.PI Cyclic Placebo Measured by DXA Fracture reduction in 
and I year RA, PMR 54 62 +0.6% (- 3.7%) subgroup ofPMP 1997[216] C.DB. Etidronate 
calcium Fern Neck +0.2 1-1.7%) women 
Wolthagen Cyclic Calcium Primary Measured by DXA Possible vitamin D P.R.C. Etidronate I year c~:~~~~s 6 6 Spine +0.4% (-3.0%) 1997[313] and calcium disorder 
Boutsen 
P.R.C Pamidronate Calcium 1 year RA,PMR 15 12 Spine +3.6% (-5.3%) No explanation for the 1997[314] and calcium Fern ,+2.2% (-5.3%) drop outs 
Two different methods 
Cyclic Placebo RA,PMR, 85 patients measured by 
of BMD measurements 
Raux P.R.PI DXA and 32 by DPA and all subjects were 
1998[211] C.DB Etidronate and 1 year Vasculitis, 51 56 Spine + 0.3% (-2.8%) uncontrolled allowed 
and calcium calcium SLE Fern Neck-I.3% (-2.6%) to take vitamin D up to 
1000!U I day 
Jenkins P.R.PI C Measured by DXA 
Etidronate and 1 year RA,PMR 15 13 1999[307] C,DB 
and cal calcium 
Spine +1.8% (-3.7%) 
Risedronate Measured by DXA 
Reid P.R.PI pooled data Placebo RA,PMR, Spine + 4,2 % in men Preliminary data 
1999[217] C.DB 2.5 and 5 mg and 1 year SLE 228 170 Premenopausal women without data on the d:~~~i~~~ calcium + 2,5 %, postmenopausal control group women + 3.8 0/0 
RA = Rheumatoid Arthritis; GC = Glucocorticoid; 1M = mtra-muscular; BMD = Bone 
Mineral Density; QCT = Quantatative Computer Tomography; DPA = Dual Photon 
Absorptiometry 
DXA = Dual energy X-ray absoptiometry 
Table 4.8.1 Clinical trials concerning primary prevention of glucocorticoid-induced osteo-
porosis with bisphosphonates. 
In the meta-analysis by Homik et al [297], a statistically significant improvement in lum-
bar BMD with a weighted mean difference of approximately + 4% was found. Also a 
statistically significant effect on femoral BMD was observed, although to a lesser extent 
(+2.1 %). Although there was a 24% reduction in spinal fractures, it did not reach statisti-
cal significance because most studies are not powered to draw conclusions about fracture 
risk and incidence. Recently Adachi et al [216] found a statistical significant reduction of 
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AuthorYr.l Study Control Diseases N N ResultsBMD Comments Medication Group Treatment group vs. (control Ref Design Rx treat plac 
Asthma QCT is not com-Collagen Reid P.R.PI Pamidronate placebo I year vascular 16 19 Measured by QCT parable to DXA in 19S5[212] C diseases Spine +19.6 % (~S.S %) percentages gain Of loss 
PMR, Measured by DXA A lot of dropouts Skingle Etidronatc and Calcium COPD 
1994[301] P.R.C calcium 2 years Temporal IS 20 Spine +4.1% (.O.S%) because of too low Fern Neck-1.0%(~1.0%) dose of prednisolone 
Etidronate 7.5 Different dosage 
Worth P.R.C. mg/kg/day, Calcium lh year Asthma 14 19 Measured by DPA regimen, only asth-1994[299] 1000 IU vit D Spine +5.5% (-4.6%) matics BMD 
Asthma, Measured by DXA Struijs Etidronale and Calcium COPD, Extremely osteoporotic 
1995[300] P.R.C. calcium 1 year temporal 19 20 Spine +5.7% (·3.4%) patients, using Z-score Fern Neck +6.S% (·4.1 %) 
Eastell P.R. PI Risedronate 2.5 Plaeebo Measured by DXA Only published in 
1996[311] C.DB mg/day 2 years RA 40 40 Spine +1.4% (-1.6%) abstract Pem Neck ·1.0% (·3.6%) 
Cyclic Rise- Placebo Measured by DXA dronate 15 rng / 2 years RA 40 40 Spine ·0.1% (.1.6%) 
Measured by DXA 
Spine +2.2%, Fem Neck- Both groups received Placebo RA,PMR 0.03% in the S rng group SOO~ 1000 rng of Saag P.R.PI Alendronate S Calcium 1 year Asthma, 137 134 Spine +2:78%, Fern Neck calcium/day and 1995[215] C.DB or 10 mg/day vitamin SLE, +0.22% in I Omg group. The Vitamin D 250·500 D pemphigus control lV/day. 
Measured by DXA 205 patients of the 
Alendronate, Spine +2.86%,Fem Neck initial study entered the 
Smg or 10 mg Placebo RA,PMR +0.0 I % in Smg group extension study and 
Liberman P.R.PI Or 2,5mg in calcium Asthma, Spine +3.86%, Fern Neck both groups received 
1999 C.DB first year vitamin 2 years SLE, 134 51 +0.62 % in 10 mg group Vitamin D (250· Spine +3.85%, Fern Neck followed by 10 D pemphigus 
·0.63% in 2.5/lOmg group 50mU) and (SOO·1000) 
mg second year (-j}.91%), Fern Neck calcium daily. Only 
abstract published 
Risedronate 5 Placebo Measured by DXA Statistical significant Reid P.R.PI and 2.5 mg calcium RA,PMR, reduction of vertebral 
1999[217] C.DB daily and calM and vitaM I year SLE 290 Spine +2.9% (+0.4%) fractures. Fem Neek + I.S% (.0.2%) 
Table 4.8.2 Clinical trials concerning secondary prevention of glucocorticoid-induced 
osteoporosis with bisphosphonates. 
new fractures in postmenopausal women on corticosteroid use, treated with etidronate. Simi-
lar results have recently been reported regarding lisedronate and alendronate [217,291]. 
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ABSTRACT 
Patients receiving long-term prednisone (7.5 mg prednisone daily for ~ 3 months), thereby 
at risk for developing steroid induced osteoporosis, were identified by using a specially 
designed computer program which screened 22 large population based databases from gen-
eral pharmacists, randomly chosen throughout the Netherlands. Concomitant data about pre-
scription of drugs used for prevention and treatment of osteoporosis were obtained. 
The investigated population consisted of 248.169 people, 157.461 subjects with a public 
insurance and 90.708 subjects with a private insurance. Nine hundred sixty-four subjects 
(532 women and 432 men, aged 4-98 years) were taking long-term prednisone (mean dose 
12.5 mg) for ~ 3 months. Of these 964 patients, 351 (36%) were taking some form of anti-
osteoporotic medication. 
The age-specific prevalence of long-term prednisone use, was calculated in the population 
with a public insurance. An age-related increase of prednisone use was observed from 
0.015% atthe age of 0-10 up to the highest prevalence (1.4%) in the age group 80-89 (over-
all prevalence of 0.27%). Our computer program can create an effective signalling system in 
identifying patients at risk for steroid induced osteoporosis. 
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INTRODUCTION 
Systemic glucocorticoids are used in the treatment of a wide variety of sometimes life-
threatening diseases. The adverse effects of long-term use of these agents are multiple and 
often setious, including steroid-induced osteoporosis which contlibutes to significant mor-
bidity [1,2]. 
The use of a supra-physiological dose of glucocorticosteroids (i.e. ~ 7.5 mg prednisone 
daily), provokes a decline in bone mass, with an accelerated bone loss in the first three to six 
months of treatment [3-5]. It has been reported that, thirty to thirty-five percent of patients 
receiving long-term glucocorticoid therapy suffer from one or more vertebral fractures. The 
overall reported risk of hip and vertebral fractures in these patients increases from 50% up to 
100% [6-8]. A steep increase in fracture risk at doses over 7.5 mg prednisone daily, is 
observed [9, 10]. 
Therefore, detennining the prevalence of patients at highest risk for steroid-induced osteo-
porosis implies the selection of patients with a daily use of more than 7.5 mg prednisone for 
at least 3 months. It has been suggested that 75,000 patients are currently being tl'eated with 
glucocorticosteroids in the Netherlands [11]. However, a more precise estimate of the preva-
lence of patients using potentially osteoporosis inducing dosages of glucocorticosteroids has 
not been calculated. 
The objective of this study was to determine the prevalence of subjects using the potentially 
harmful dosage of > 7.5 mg of prednisone and to estimate the use of medication for preven-
tion and treatment of osteoporosis in the Netherlands. 
METHODS 
Out of 650 pharmacists in the Netherlands, with a specific "Euroned" database system, 25 
were randomly selected, coveting the whole Dutch geographic, including both urban and 
rural areas. The pharmacists were first approached by mail and then personally invited to 
take part in the survey, resulting in the participation of 22 of them. Three resigned by lack of 
motivation. 
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A specially designed computer program, extracting patients with long-term use of pred-
nisone subsequently examined the databases. The most commonly prescribed steroid was 
prednisone, in 98% of the cases. Therefore, the further analysis was restricted to this gluco-
corticoid. From the selected patients we recorded: age, sex, steroid daily dose, duration of 
therapy, public or private insurance and co-prescription of anti-osteoporotic drug as used in 
the prevention and treatment of corticosteroid-induced osteoporosis in the Netherlands. (See 
table 1.) The legend duration (prescription length) was calculated by dividing the number of 
filled tablets or capsules by the described daily number. Concommitant medication was 
defined as any drug of which the legend duration overlapped with the legend duration of the 
index drug. The index drug was defined as all orally given prednisone, A TC code 
H02AB07. 
Anti-osteoporotic drugs (ATe-code) 
Calcium (A12AA) 
Bisphosphonates (M05BA,M05BB) 
Vitamin D (AI ICC) 
• HRT (Estradiol, conjugated estrogens and combin-
tions with progestagens) 
(G03CA,G03DC, G03FA, G03FB) 
Table 1 
Health care in the Netherlands is divided through a system of public and private insurance 
schemes. Almost all subjects with a public insurance are registered at the pharmacy, even 
those not on any medication. Therefore, we were able to detelmine the exact prevalence, in 
the year 1998, for the use of long-telm prednisone in subjects with a public insurance in the 
Netherlands. The study was approved by the Medical Ethical Committee. 
RESULTS 
The total examined population comprised 248.169 subjects of which 157.461 with a public 
and 90.708 with a private insurance. Out of the total popUlation, 964 patients used ~ 7.5 mg 
of prednisone for longer than 3 months, with a mean dose of 12.5 mg per day (fig 1). Age in 
the patient group ranged from 4-98 (median 69) years, 532 were women (fig 2). 
Of this 964 patients 351 (36%) received some form of medication used in prevention or 
treatment of osteoporosis. Of the prednisone treated patients an avarage of 36% used any 
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form of anti-osteoporotic treatment. In those below 40 years of age this percentage declined 
to around 25% (Fig. 3) The co-medication comprised calcium (26%), bisphosphonates 
(40%), vitamin D (6%), vitamin D with calcium (16%), vitamin D with cyclic calcium and 
bisphosphonates (4%) and honnone replacement therapy (8%) (Fig 4). 
From the overall population, we separated the group of 157.461 people with a public insur-
ance of whom we had the exact data about users and non-users of medication. This group 
had an age-sex distribution similar to that of the general population in the Netherlands as 
compared to population figures of 1998 provided by the Dutch Central Bureau of Statistics. 
In this population the overall prevalence of prednisone use ~ 7.5 mg for more than 3 months 
was 0.27%. A steep increase was observed in people over 55 years of age, with a mean 
prevalence of 0.77%, with a subsequent decline in the oldest group. In those in the age 
group 80-89 over 80 years old the prevalence was 1.4% (fig 5). 
DISCUSSION 
Very few studies have estimated the prevalence of long-telm use of systemic corticosteroids 
in the general population [12,13]. In 1996, Walsh et al. reported that, inespective of dose, 
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0.5% of the Nottinghamshire population in the United Kingdom was taking long-term glu-
cocorticosteroids with a median dose of 6.8 mg daily. 
We are the first to determine the prevalence of patients at risk for steroid-induced osteoporo-
sis using a daily dose of at least 7.5 mg prednisone for longer than 3 months. We found a 
prevalence of 0.27% in the total population and 0.77% of people over 55 years. The latter 
comprises women who are ah'eady at risk for osteoporosis given their postmenopausal status 
[14]. 
The steep increase in prevalence in the elderly is impressive, reaching a prevalence of 1.4% 
in patients in their eighties. In people over 90 years of age there was a gradual decline in 
prevalence of glucocorticoid use, which is probably due to a lower incidence of diseases for 
which prednisone is prescribed. Another explanation is that the very elderly reached this old 
age due to their healthy constitution and therefore not using glucocorticoids. 
Unlike Walsh et al [12] we observed no statistically significant difference in the age specific 
prevalence between men and women (fig 3). Probably because we focussed on the higher 
dosages of prednisone taken for at least three months. Also the social class of the selected 
population could be a factor. Due to the different registration of private and public insured 
subjects in the pharmacists' database, we were only able to calculate the prevalence in the 
public insured subjects which represents a group with a lower income. Nevertheless, the age 
distribution in the population examined was similar to the Dutch population at large. If we 
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extrapolate our prevalence figures to the total Dutch population (15.6 million in 1998), at 
least 40.000 people are at high risk for steroid induced osteoporosis. TIus figure corresponds 
with estimations of 75.000 people using glucocOliico-steroids overall [II). Our determina-
tion of prevalence is certainly an underestimation since our study was limited to the outpa-
tient population and missed patients using repeated short-term prednisone courses. Further-
more, we excluded other glucocorticoids, such as dexamethasone, since their use in the gen-
eral population is very low [11,12]. 
Prevention therapy for steroid induced osteoporosis is only given in a minority of patients 
receiving glucocorticosteroids [IS). This is probably due to the low awareness of the long-
term adverse effects of glucocorticoids on the skeleton, even when it is used in a relatively 
high dose [16] [17]. 
In our study, 36% of the patients at risk received a prescription of any fOlm of an anti-osteo-
porotic prescription. Adult patients younger than 40 years used even less prophylactics, only 
around 25% (fig 4). Yet this percentage is higher than found by Walsh et al in the UK, who 
reported use of anti-osteoporotic medication in only 14% of patients using oral glucocorti-
costeroids. We probably overestimated the use of co-prescription, since estrogen and prog-
estagen or combined use will be also prescribed for other reasons than osteoporosis. Even 
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without hormone prescription the co-prescription figure is still higher than the 14% deter-
mined by Walsh et al probably due to recent growth in awareness of the adverse effects of 
glucocorticoids on bone and implementation of guidelines, such as proposed by The Ameri-
can College of Rheumatology [18] and recently the United Kingdom Consensus Group 
[19,20]. 
From this study, it appeared that a substantial number of subjects are at risk for steroid 
induced osteoporosis, while only in a minority of cases preventive measurements have been 
taken. Most countries focussed on case finding conceming glucocorticoid-induced osteo-
porosis. Our method of extracting patients at risk with a computer program could provide a 
tool that is easy to use in the identification of long-tenn glucocorticoid users in general prac-
tice. For example, extracting patients at risk from a database of 10,000 takes about 15 min-
utes, and provides detailed information about dose and duration of steroid therapy, with per-
sonal data available only to the pharmacist and general practitioner. Provided that pharma-
cists have automated records of prescription, its use in daily practice may create a signalling 
system, ultimately resulting in a better identification of patients at risk for glucocorticoid-
induced osteoporosis. 
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CHAPTER 6 
THE EFFECTS OF INHALED GLUCOCORTICOIDS ON 
BONE MASS AND BIOCHEMICAL MARKERS OF BONE 
HOMEOSTASIS 
- A ONE YEAR STUDY OF BECLOMETHASONE VERSUS BUDESONIDE -
A. Struijs MD and H. Mulder MD, PhD 
(Published as "The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone 
homeostasis: a 1 year study ofbeclomethasone versus budesonide". Neth J Med 1997;50:233-237) 
SUMMARY 
Bone mass and biochemical bone markers were prospectively studied in 33 patients with 
chronic obstructive pulmonary disease treated during one year with inhaled beclometha-
sone 200 J-Ig/Q.I.D.(Group A; 8 men and 4 women), inhaled budesonide 200 J-Igi 
Q.I.D.(Group B; 6 men and 5 women), or not requiring steroids (Group C; 6 men and 4 
women). Both inhaled corticosteroids decreased serum concentrations of the osteoblastic 
markers osteocalcin and carboxy terminal propeptide of type I collagen (PICP). The 
osteoclastic marker cross-linked carboxy terminal telopeptide of type I collagen (ICTP) 
increased significantly more in patients on beclomethasone than in those on budesonide. 
The decrease in bone mineral density (BMD) was more pronounced in patients treated 
with beclomethasone (l.l % in the spine; 1.7% in the hip; p < 0.05) compared to those 
treated with budesonide (0.6% in both spine and hip) or in the control group. Inhaled cor-
ticosteroids affect biochemical bone markers and bone mineral density, but there is dif-
ferent effect for the two corticosteroids evaluated in the present study. 
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KEYWORDS 
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INTRODUCTION 
High doses of glucocorticoids constitute effective treatment of bronchial asthma and 
chronic obstructive pulmonary disease (COPD). Unfortunately they decrease intestinal 
absorption of calcium and increase calcium excretion in urine, both in animals and in 
man [1-7]. This negative calcium balance leads to secondary hyperparathyroidism with 
increased bone resorption and decreased bone formation [8-10]. 
Previous studies in asthmatic patients simultaneously treated with oral prednisolone and 
inhaled glucocorticosteroids, demonstrated a marked decrease in bone mass and changes 
in several parameters of bone homeostasis [11-13]. 
We measured the effects of inhaled beclomethasone and budesonide on bone mass and 
several biochemical parameters of bone homeostasis in patients with chronic obstructive 
pulmonary disease (COPD). 
PATIENTS AND METHODS 
Between February 1st, 1991 and January 31st, 1992,39 patients with COPD living in the 
Rotterdam area, and not previously treated with glucocorticosteroids were recruited. 
Patients were excluded if they had any disease affecting bone or calcium metabolism, or 
were taking medication such as vitamin D, estrogens, calcitonin, bisphosphonates, or flu-
oride. A complete history was taken and physical examination petformed in each patient 
before the initiation of therapy; laboratOlY evaluations included semm chemistry and urinary 
analysis. If a patient dropped out of the study, the scheduled protocol will be followed 
(intention to treat). The procedures followed were in accord with guidelines of the 
Helsinki declaration for physician-initiated studies. 
After giving their informed consent, patients requiring glucocorticoids were randomised 
to beclomethasone aerosol 200 Ilg four times daily (Group A) or budesonide 200 Ilg four 
times daily (Group B); patients not requiring glucocorticoids constituted Group C. 
Patients were considered as drop-out if they needed oral glucocorticoids during the 
study, if measurements of BMD or of blood chemistry were not performed according to 
protocol, or if patients in group C were treated with either oral or inhaled glucocorticoids 
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during follow-up. 
Vertebral (Ll-L4) and hip bone mineral density (BMD) were measured by dual energy 
X-ray absorptiometry (HOLOGIC QDR 1000) by a technician blinded to treatment 
assignment, at baseline and after 6 and 12 months of treatment. 
Serum calcium and alkaline phosphatase were measured with an Autoanalyser. Carboxy-
terminal propeptide of type I collagen (PICP) and cross-linked carboxy terminal telopep-
tide of type I collagen (ICTP) were determined by radioimmunoassay (Orion Fat'mos, 
Turku, Finland), with an intra- and interassay CV of respectively 4.7% and 5.3% for 
PICP and 6.2% and 7.9% for ICTP. Osteocalcin was determined by radioimmunoassay 
(Inestar Corporation; Stillwater MN, USA; intra- and interassay CV were respectively of 
3.8% and 4.3%). 
STATISTICS 
Data shown as mean ± SEM; one-sample t-tests for between groups changes (Minitab 
5.1, Minitab Inc, State College of Pennsylvania) were used, confidence interval 95%, p < 
0.05 is considered statistical significant. 
RESULTS 
Initially 39 patients during the study period were included. One patient from Group 
A and one from Group B were treated with oral glucocorticoids and one patient in 
Group C with inhaled glucocorticoids; one patient in Group B and two in Group C 
were excluded because of incomplete laboratory analyses and BMD determinations. 
The remaining 33 patients completed the study. Beclomethasone and budesonide 
were well tolerated; no discontinuation of study drugs because of side effects was 
observed. The efficacy of beclomethasone and budesonide was the same in both 
treatment groups. Group A consisted of 8 men and 4 women (1 postmenopausal) 
between 36 and 75 years old (mean age: 46 years) and received beclomethasone. 
Group B consisted of 6 men and 5 women (1 postmenopausal) between 34 and 79 
years old (mean age: 49 years) and received budesonide. Group C included 6 men 
and 4 women (2 postmenopausal), between 28 and 81 years old (mean age: 50 
years), and received no glucocorticoids. Inhaled corticosteroids were prescribed 
mainly to patients with asthma with an extrinsic component. The patients were able 
to perform all daily activities without help from others and the mobility in the differ-
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ent groups was about the same. 
Mean serum concentrations of calcium and of bone markers are listed in table 1. 
Osteoblastic markers (alkaline phosphatase, osteocalcin, and PICP) decreased in groups 
A and B and were unchanged in Group C. The osteoclastic marker ICTP increased only 
in Group A. 
Changes in biochemical bone markers after 12 months of treatment are given as percent-
ages in table 2. All measurements were unchanged in Group C. Alkaline phosphatase, 
osteocalcin, and PICP decreased similarly and significantly in both groups on inhaled 
glucocorticosteroids. ICTP increased only in patients on beclomethasone. BMD data are 
listed in table 3. Mean BMD slightly decreased in all groups; no change was statistically 
significant. A statistically significant percentual decrease in lumbar spine and hip BMD 
was observed only in patients on beclomethasone (fig. 1 ). 
DISCUSSION 
Osteoporosis is a well-known and serious complication of prolonged oral treatment with 
glucocorticoids, but only limited data are available for patients inhaling these drugs [11-
13]. Cross-sectional studies on bone density lack properly matched controls, and include 
confounding variables such as previous courses of oral glucocorticoids. A decrease in 
osteoblastic markers (alkaline phosphatase and osteocalcin) and an increase in the osteo-
clastic marker hydroxyproline have been reported [12]. This suggested, depressed bone 
formation associated with increased bone resorption. 
Previous studies [11-13] on the effects of inhaled glucocorticoids on bone mass and 
biochemical markers of bone and calcium homeostasis have documented an 8% 
decrease in bone mass in asthmatic patients simultaneously treated with oral pred-
nisolone [11], and a decrease in the osteoblastic marker serum osteocalcin after 8 
days of treatment with inhaled glucocorticosteroids in 8 healthy volunteers [12]. 
Inhaled budesonide and beclomethasone decreased osteoblastic function and 
increased bone resorption, with a significant decrease in serum alkaline phosphatase 
and an increase in the urinary hydroxyproline/creatinine ratio [13]. We also found a 
decrease in bone formation associated with an increase in bone resorption. The 
decrease in osteocalcin concentrations seems to be a dose-dependent effect of inhaled 
glucocorticoids [14]. The percentual decrease in the osteoblastic marker PICP was 
more pronounced than the decrease in alkaline phosphatase or in osteocalcin; as PICP is 
formed in a 1: 1 molar ratio to collagen, this is a more direct measure of on-going bone 
formation [14]. The more pronounced decrease observed in patients on beclomethasone 
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TABLE 1 
Serum Levels of Calcium, Alkaline Phosphatase, Osteocalcin, PICP and ICTP Before and During 
Glucocorticosteroid Inhalation Therapy (mean ± SEM) 
Before 3 Months 6 Months 9 Months 12 Months 
Serum Ca (mm01/l) Beclomethasone 2.30 ± 0.02 2.30 ± 0.03 2.30 ± 0.02 2.31 ± 0.02 2.30± 0.02 
Budesonide 2.31 ± 0.02 2.30 ± 0.02 2.30± 0.02 2.32 ± 0.02 2.30 ± 0.02 
Control 2.28 ± 0.Q3 2.29± 0.02 2.31 ± 0.03 2.32 ± 0.02 2.31 ± 0.02 
Alkaline phosphatase Beclomethasone 64± 4 57 ± 3 55 ± 4' 52 ± 5' 54± 4' 
(Uti) Budesonide 64±4 56 ± 3 63 ± 3 52 ± 3' 53 ± 3' 
Control 62± 5 65± 4 65 ± 4 64± 4 64±4 
Beclomethasone 2.85 ± 0.5 2.63 ± 0.4' 2.61 ± 0.4' 2.52 ± 0.41 2.49 ± 0.5' 
Osteoca1cin (I-Igll) Budesonide 2.79 ± 0.6 2.65 ± 0.5 2.51 ± 0.5' 2.45 ± 0.51 2.50± 0.5' 
Control 2.76 ± 0.5 2.77 ± 0.4 2.74 ± 0.5 2.75 ± 0.4 2.78 ± 0.6 
Beclomethasone 214 ± 14 171 ± 12' 171 ± 14' 168 ± 111 148 ± 121 
PICP (I-Igll) Budesonide 223 ± 10 188 ± ll' 185 ± 9' 164 ± 10' 161 ± 9' 
Control 204 ± 12 206 ± 10 200 ± 10 205 ± II 20S ± 10 
Beclomethasone 3.0 ± 0.3 3.2 ± 0.3 3.2 ± 0.2 3.6 ± 0.2' 3.4 ± 0.3' 
ICTP (I-Igll) Budesonide 2.9± 0.2 2.9 ± 0.3 3.l ± 0.3 3.2 ± 0.4 3.0± 0.3 
Control 2.S ± 0.2 2.9± 0.3 2.9 ± 0.2 3.0± 0.3 2.9 ± 0.2 
Significance compared to the pre-treatrnentvalue: 'P <0.05, 1 P <0.01. 
TABLE 2 
Percentage of Change (mean ± SEM) (12 Months) Compared to the Pre-treatment 
Value of Bone Markers in Patients Using Inhaled Glucocorticoids 
A1k. Phosphatase Osteocalcin (p.gII) PICP (p.gII) ICTP (p.gII) 
Group A 
GroupB 
Group C 
(UtI) 
-15.6 ± 1.0' 
-17.2 ± 1.3' 
+3.2 ± 0.4 
-12.6 ± 1.9' -30.9 ± 3.71 
-10.4 ± 1.S' -2S.7 ± 4.01 
+0.7 ± 0.4 +2.0 ± 1.5 
A = inhaled beclomethasone; B = inhaled budesonide; C = control group. 
'p <0.05 compared to control group. 
lp <0.01 compared to control group. 
'P <0.05 compared to group B and control group. 
§ P <0.05 group B compared to group A. 
TABLE 3 
BMD Values of the Lumbar Spine (mean ± SEM) and 
Total Hil) Before Treatment and During Treatment in 
COPD Patients 
Before 6 Months 12 Months 
BMDlumbar 
spine 
(g Ca/em2) 
Group A 1.l01±0.019 1.092±0.020 1.089±0.014 
GroupB 1.096±0.018 1.091±0.016 1.090±0.01S 
Group C 1.0S5±0.021 1.0S3±0.020 1.0SO±0.020 
BMD total hip 
(g Ca/em2) 
Group A 0.884±0.015 0.S74±0.018 0.S69±0.014 
GroupB 0.S75±0.018 0.872±0.021 0.870±0.022 
GroUl' C 0.S69±0.020 0.873±0.01S 0.S67±0.016 
A = inllllled beclomethasone; B = inhaled budesonide; C = 
control group. 
+l3.3 ± 1.2' 
+3.4 ± 1.9§ 
+3.6 ± 1.0 
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Mean (± S.E.M.) percentage of change in spine and hip BMD (12 months vs 
baseline) in patients using inhaled glucocorticosteroids 
(A = inhaled beclomethasone; B = inhaled budesonide; C = control group) 
% 
group A IZl group B D group C 
* p<O.05. Percent change from baseline after five days. 
suggests a stronger inhibition of bone formation compared to budesonide. However the 
number of patients are too smaJI to draw straightforward conclusions. Serum osteoca1cin 
also decreased more on beclomethasone than on budesonide [13]. The osteoclastic mark-
er ICTP increased on beclomethasone, but not on budesonide. 
The impact on bone mass of these different effects on osteoblast and osteoclast of these 
drugs was reflected in the significant percentual decrease in BMD of the lumbar spine 
and of the hip in patients on beclomethasone, not in those on budesonide. The decrease 
in BMD was similar in the femoral neck area, in Ward's triangle, and in the total hip 
bone, but less than the 8% decrease reported by Reid [10], whose patients were also on 
oral glucocorticoids. Budesonide seems to affect bone mass less than beclomethasone, 
probably because of its different bioactivity and four times faster degradation into inac-
tive metabolites [15-20]. Although the number of patients are too small to draw straight-
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forward conclusions. Our observations warrant a large prospective study with a long fol-
low-up period to evaluate the influence of inhaled glucocorticoids on bone formation and 
resorption. 
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SUMMARY 
Objectives. To study the acute short term effects on the biochemical parameters of calci-
um and bone homeostasis in postmenopausal women treated with high dose of pred-
nisone alone or with additional etidronate, before and during 5 days of treatment. 
Methods. Serum calcium, phosphorus, creatinine, alkaline phosphatase activity, osteocal-
cin, carboxy terminal propeptide of type I procollagen (PICP), cross-linked carboxy ter-
minal telopeptide of type I collagen (ICTP), PTH, 25 hydroxy vitamin D and urinary 
excretion of calcium over 24 hours were measured before and during 5 days of treatment 
in fourteen postmenopausal women treated with high dose of prednisone (60 mg/day) 
alone (group A) or combined with cyclical etidronate (group B). 
Results. Significant differences from baseline were found in osteocalcin and urinary 
excretion of calcium in both groups and for ICTP in group B. Significant differences 
between groups were calculated at day 5 of the study for osteocalcin, ICTP and 24 hours 
of urine calcium excretion (p < 0,01). Urinary excretion of calcium over 24 hours 
increased in group A (+ 14.7%; p < 0,05) and decreased in group B (- 22.1 %; p < 0,01). 
Osteocalcin levels decreased in group A (-38.1 %) and increased in group B (+27.4%; 
both p < 0,01). ICTP decreased only in group B (-19.4%; p < 0,01). 
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Conclusions. The results are consistent with the fact that etidronate is able to acutely pre-
vent bone resorption due to corticosteroids. The increase in osteocalcin in the etidronate 
treated group is a new feature. A direct or indirect (PTH, 1,25 vitamin D) stimulatory 
effect of etidronate on the osteoblast cannot be excluded. 
KEYWORDS 
Prednisone, corticosteroid, glucocorticoid, etidronate, bisphosphonate, osteoporosis, cal-
cium metabolism and bone markers. 
INTRODUCTION 
Osteoporosis and pathological fractures due to use of prednisone, in a daily dosage of 
more than 7,5 mg for periods longer than 6 months have been recognised for a long time 
[1-3]. However the contribution of different pathofysiological mechanisms is still 
unclear. Supraphysiologic doses of glucocorticosteroids, given to animals and men result 
a negative calcium balance [4-7], which is associated with secondary hyperparathy-
roidism contributing to further calcium and bone loss [7-9]. Also direct effects of gluco-
corticosteroids on osteoblasts have been described [10-12]. Nowadays it becomes clear, 
that with the use of glucocorticosteroids for shorter or longer time period's [13], an 
uncoupling between bone resorption and formation occurs. Chronic use of glucocortico-
steroids increases resorption and decreases formation, which leads to the development of 
osteopenia and fractures [2,3,14]. 
Different treatment modalities as hormone replacement therapy, calcitonin, fluor and bis-
phosphonates have been used to prevent or treat low bone mass due to glucocortico-
steroids [15-24]. We and others found a pronounced increase of BMD in patients with 
steroid induced osteoporosis treated with etidronate or alendronate [21-24]. The results 
suggested an additional effect of bisphosphonates apart from decreased resorption alone. 
No data however have been published dealing with the acute effect of bisphosphonates 
on glucocorticoid- induced changes in circulating bone markers. The objective of the 
current study was to determine the short-term effect of the bisphosphonate etidronate on 
glucocorticoid-induced changes in biochemical parameters of calcium and bone home-
ostasis in postmenopausal women with temporal arteriitis treated with high dosage of 
glucocorticosteroids. 
ACUTE EFFECTS OF ETIDRONATE 103 
PATIENTS AND METHODS 
Study design 
This prospective randomised open-label study was conducted in an outpatient clinic. 
Within a time period of twelve months fourteen postmenopausal patients with histologi-
cal proven temporal arteriitis were randomly allocated to the following treatments: high 
dose of prednisone (60 mg/daily) alone (group A) or high dose prednisone (60 mg/daily 
with etidronate 400 mg daily (group B) for five days. Patients with any disease or med-
ication that could interfere with calcium or bone metabolism were excluded from the 
study. All patients gave informed consent to the study. The procedures followed were in 
adherence with the guidelines of the Helsinki declaration for physician initiated studies. 
The study participants took their prednisone at 8.00 a.m .. The patients in group B 
received 400 mg etidronate one hour before prednisone intake. Breakfast was served at 
9.00 a.m. The patients had a dietary calcium intake of 400-800 mg before the study and 
they were kept on this level during the study. 
Measurements 
Blood and urine were collected at 7.00 a.m. daily for five days starting one day before 
any medication was taken. The following biochemical parameters were evaluated before 
and during the first five days of treatment: serum calcium, phosphorus, creatinine, alka-
line phosphatase activity, osteocalcin, carboxy terminal propeptide of type I pro collagen 
(PICP), cross-linked carboxy terminal telopeptide of type I collagen (ICTP), PTH and 25 
hydroxy vitamin D. Urinary excretion of calcium over 24 hours was measured daily from 
day -1 to day 5. The serum and urine calcium, serum phosphorus, alkaline phosphatase 
and creatinine were measured by autoanalyzer techniques. The samples for hormonal 
measurements were immediately frozen and stored at -20°C until use. All hormonal 
measurements were performed in a one assay session. 
The radio immunoassay (RIA) used for osteocalcin measurements was the commercial 
available kit of Incstar Corporation, Stillwater Minnesota, USA (intra-interassay coefficient 
of variation (CV) 3,8% and 4.3% respectively; sensitivity of the assay was 0,5 /lg/l; normal 
values 1,8-6,6 /lg/I). PICP and ICTP results were obtained with RIA produced by Fat'mos 
Diagnostica (Orion Corporation Fatmos P.O. Box 425, SF-20101 Turku Finland). The intra-
and interassay CV were 4,7% and 5.3% for PICP and 6.2% and 7.9% for ICTP. 
Sensitivity was 1,2 /lg/I for PICP and 0,43 /lg/l for lCTP; normal values PICP, 50-170 
/lg/l and 1 CTP 1,4-5,4 /lg/l. PTH was measured by a two-side RIA. The first step 
involved extraction and concentration of plasma PTH using solid phase anti-amino-terminal 
antibodies. After elution, the PTH immunoextract was analyzed using a sensitive mid- and 
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C-region immunoassay [25]. The intra- and interassay CV were 8.3% and 10.2% respective-
ly; the sensitivity of the assay was 0.8 pmol/l (normal values 0.8-5.0 pmol/l). 
Serum 25- OH-D was quantified, after acetonitrile extraction, using a direct commercial 
RIA (Incstar Corporation, Stillwater, MN, USA). The intra- and interassay CV were 
6.3% and 13.0% respectively (normal values 25-125 nmol!l). 
Statistics 
Data were expressed as mean ± SEM, with 95% confidence intervals of the mean. The 
significance of change from baseline was determined by a paired t-test, SPSS windows 
version 8.0 (p denoted by p). The significance of difference between means of biochemi-
cal parameters, at the end of the study (day 5), was determined by an independent two-
sample t-test (p denoted by p*). Also analysis of covariance (ANCOVA, with mean pre-
treatment values determinations and time as covariable) was performed to compare the 
differences between groups at day 5 of the study. Differences were considered statistical-
ly significant when p < 0.05. 
RESULTS 
Fourteen postmenopausal women were randomised to group A and group B. Each group 
comprised seven women. At baseline the two treatment groups were comparable in age 
and biochemical parameters. Group A; n= 7; mean age 72 yr., range 59-82 yr. Group B; 
n=7; mean age 74 yr., range 63-82 yr. The results are given in Table 1 and illustrated for 
osteocalcin (Fig. I ), urinary excretion of calcium over 24 hours (Fig. 2) and the telopep-
tide ICTP (Fig. 3). In both groups of prednisone alone and combined prednisone and 
etidronate treatment serum calcium and phosphate levels, alkaline phosphatase PTH and 
25 OH vitamin D levels virtually remained unchanged. 
In the prednisone alone group, serum osteocalcin levels significantly decreased from 2.7 
± 0.3 mg/L at baseline to l.7 ± O.l mg/L after 5 days (- 38,1 %, p < 0.01). In contrast to 
the combined treatment group serum osteocalcin levels steadily increased from 2.4 ± 0.3 
mg/L at baseline to 3.0 ± 0.4 mg/L after 5 days (+ 27.4%, p < 0.01). The A change in 
osteocalcin between the two groups was statistically significant from day 3 (p* < 0.05). 
The procollagen I levels remained unchanged in both treatment groups. 
The bone resorption marker ICTP remained virtually unchanged during prednisone treat-
ment alone, but instead gradually decreased in the bisphosphonate group to levels 19.4% 
below baseline at day 5 (p < 0.01). At that time the difference between both groups was 
statistically significant (p* < 0.01). Urinary calcium excretion gradually increased over 
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Figure 1. Time course of serum osteocalcin (mean:l: SEMI. 
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Table 1. Biochemical markers of calcium and bone homeostasis (mean + SEM and 95% Cil. 
(group A: prednisone; group B: prednisone and etidronate) 
Group Before Day 0 
SeCa A 2.36± 0.04(2.26-2.46) 2.35± 0.04(2.26-2.43) 
(mmoln) B 2.34± 0.05(2.23-2.45) 2.32+ 0.05(2.20-2.44) 
SeP04 A 1.12±0.07(0.95-1.28) 1.12±0.06(0.96-1.26) 
(mmoln) B 1. 1 0±0.08(0.91-1.28) 1.08+0.07(0.91-1.25) 
Uca A 6.5 ± 0.6 (5.1-7.9) 6.6 ± 0.7 (4.8-8.4) 
(mmoln) B 6.2 + 0.8 (4.3-8.1) 6.2 + 0.7 (4.3-8.0) 
Alk Phosph A 62 ± 6.3 (46 - 77) 61 ± 5.8 ( 47 - 75) 
(U/I) B 61 ± 4.3 (51 - 72) 61 + 3.9 ( 52 - 71) 
Osteocalcin A 2.7 ± 0.3 (1.9-3.5) 2.7 ± 0.3 (1.9-3.5) 
(mg/I) B 204 ± 0.3 (1.6-3.2) 2.3 ± 0.3 (1.6-3.0) 
Procollagen1 A 217 ± 41 (116-318) 213 ± 38 (119-307) 
(~gr) B 266 ± 53 (136-395) 260 ± 52 (133-388) 
Telopeptide A 3.0 ±0.4(2.0-4.1) 3.0 ± 0.4 (2.1-3.9) 
I (~gr) B 3.0 + 0.6 (1.5-4.4) 3.0 ± 0.6 (1.4-4.5) 
PTH A 1.9 ± 0.3 (1.1-2.6) 2.0 ± 0.3 (1.1-2.8) 
(PmoVI) B 1.6 ± 0.2 (1.0-2.1) 1.6 +0.2(1.1-2.1) 
Kreatinine A 94 ± 4.5 (83-105) 95 ± 4.7 (83-106) 
(~oVl) B 93 ± 4.2 (83-104) 90 ± 3.4 (82- 99) 
250HVrl:D A 42 ± 7.4 (24 - 60) 41 ± 6.9 (23 - 58) 
(nmoVI) B 43 ± 4.7 (31 - 54) 44 ± 4.7 (32 - 55) 
1 P < 0.01 difference from baseline after fIVe days 
2 P < 0.05 difference from baseline after five days 
3 p. < 0.01 difference between groups after five days 
Day 1 Day 2 Day 3 Day 4 
2.37± 0.04(2.26-2.47) 2.35±0.05(2.24-2.46) 2.35±0.04(2.26-2.43) 2.34±0.04(2.24-2.44) 
2.30+ 0.04(2.21-2.39 2.33±0.04(2.23-2.41 ) 2.34±0.04(2.24-2.43 2.33+0.04(2.23-2.42 
1.14±0.06(1.00-1.28) 
1.10+0.06(0.94-1.26) 
1.18±0.06(1.02-1.33) 
1.07+0.07(0.91-1.24) 
1.10±0.07(0.94-1.27) 
1.11+0.07(0.93-1.29i 
1.12±0.07(0.95-1.29) 
1.08+0.06(0.92-1.24 
604 ± 0.8 (4.4-804) 
5.9 + 0.9 (3.7-8.1) 
7.2 ± 0.7 (5.4-8.9) 
5.6 ± 0.8 (3.7-7.4) 
7.1 ± 0.9 (4.9-9.3) 
5.0 ± 0.6 (3.5-8.6) 
7.2 ± 0.9 (5.0-9.3) 
4.9 + 0.7 (3.1-8.7) 
61 ± 5.0 (48-73) 
62 + 4.3 (52-79) 
62 ± 5.7 (49 - 77) 
62 + 5.1 (51-76) 
62 ± 6.2 (46 - 77) 
61 ± 4.7 (50 -73) 
60 ± 5.9 (46 - 75) 
63 + 3.9 (53 - 72) 
2.6 ± 0.3 (1.9-3.3) 2.0 ± 0.2 (1.4-2.6) 1.9 ± 0.2 (1.5-2.2) 1.7 ± 0.2 (1.3-2.1) 
204 ± 0.3 (1.7-3.1) 2.5 ± 0.3 (1.7-3.2) 2.8 ± 0.3 (1.9-3.6) 3.0 ± 0.4 (2.0-4.0) 
207 ± 35 (120-293) 206 ± 43 (102-310) 213 ± 37 (123-303) 220 ± 45 (108-331) 
268 ± 54 ( 136-400) 275 ± 49 (155-395) 277 ± 53 (148-405) 272 ± 49 (153-391) 
3.0 ±0.4(2.1-4.0) 3.1 ± 0.4 (2.2-4.0) 3.1 ± 0.4 (21-4.1) 3.1 ± 0.3 (2.3-4.0) 
2.8 ± 0.5 (1.5-4.2) 2.9 ± 0.6 (1.5-4.3) 2.4 ± 0.6 (1.4-4.1) 2.7 + 0.6 (1.3-4.1) 
2.0 ± 004 (1.1-2.8) 
1.6 + 0.2 (1.1-2.2) 
2.1 ± 0.3 (1.3-2.9) 
1.5 ± 0.2 (1.1-1.9) 
2.0 ± 0.3 (1.2-2.8) 
1.6 ± 0.2 (1.2-2.1) 
2.2 ± 0.4 (1.3-3.1) 
1.7 ± 0.2 (1.3-2.2) 
93 ± 5.4 (79-106) 93 ± 3.1 (86-101) 92 ± 4.9 (80-105) 91 ± 4.8 (78-103) 
93 ± 3.7 (84-102) 90 ± 3.8 (81-100) 94 ± 4.2 (84-104) 93 ± 4.4 (82-104) 
42 ± 6.4 (27 - 58) 42 ±7.1 (24-59) 42 ± 7.4 (24 - 60) 42 ± 7.8 (23 -61) 
44 ± 404 (33 - 54) 43 ± 5.4 (30 - 56) 41 ± 4.6 (30 - 52) 42 ± 5.5 (28 - 56) 
DayS 
2.34±0.04(2.25-2.44) 
2.34+0.05(2.23-2.45) 
1.11±0.07(1.00-1.2;j 
1.03+0.06(0.88-1.17 
7.5 ± 0.8 (5.5-904) 2, 
4.8 ± 0.6 (3.4-8.1) 1,3 
61 ± 5.8 (47 - 75) 
64 ±4.1 (54-74) 
1.7 ± 0.1 (1.4-2.0) 1,3 
3.0 ± 0.4 (2.2-3.9) 1,3 
219 ± 36 (131-307) 
279 ± 54 (144-409) 
3.2 ± 0.3 (2.4-4.0) 3 
2.4 ± 0.5 (1.2-3.7) 1,3 
2.1 ± 0.4 (1.2-3.0) 
1.9 + 0.2 (1.5-2.4) 
95 ± 4.3 (84-105) 
92 ± 3.2 (85-100) 
43 ± 7.5 (25 - 62) 
43 ± 4.6 (31 - 54) 
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five days in the prednisone alone group ( + 14.7%, p < 0.05) but decreased in the com-
bined prednisone etidronate group (- 22.1 %, p < 0.01). The difference in urinary calcium 
excretion between both groups was already statistically significant from day 3 on. Every 
patient completed the study and the study drug was well tolerated. 
DISCUSSION 
Short term high dose glucocorticoid therapy in postmenopausal women with florid arteri-
itis temporalis resulted in acute changes in bone formation and resorption as reflected by 
a 38% decrease of osteocalcin -not PICP or Alkaline Phosphatase- and a 15% increase in 
urinary calcium excretion. The glucocorticoid induced changes in bone remodelling 
markers have been attributed to a decrease in differentiated function of mature osteoblast 
leading to a decrease in osteocalcin transcription and -not in this study- a decrease in 
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type I collagen expression and increase in its degradation [10-12,26,31]. Other studies 
administering 10 to 20 mg of prednisone daily for 1 week to healthy men found a similar 
decrease in osteocalcin (-35%) and increase in urinary calcium (+45%) as we did, how-
ever, they reported a decrease in PICP [27,28] and both decreased [27] and increased 
[28] ICTP has been reported. This could be explained by the different dosages of pred-
nisone and/or the difference in study population. Similar results were obtained, in 
patients with rheumatoid arthritis given high dose of dexamethasone [13], in patients 
with multiple sclerosis given huge intravenous doses of methyl prednisolone [29] and 
after high dose corticosteroid inhalation [30]. From the present study it appears that com-
bined etidronate and glucocorticoid administration acutely reversed glucocorticoid 
induced suppression of bone formation as reflected by a 27% increase in osteocalcin 
within five day's. Urinary calcium excretion decreased from + 14.7% in the prednisone 
alone group to -22.1 % in the combined therapy group, indicating attenuation of bone 
resorption. This was also illustrated by a decrease in ICTP. This decrease of bone resorp-
tion markers is well known in chronically bisphosphonate treated patients on glucocorti-
coids, but never has been reported after such short time interval as in this study. 
The increase in osteocalcin levels during short term etidronate administration in gluco-
corticoid treated patients is, however remarkable, although we must be careful to extrap-
olate our short-term study results to the long-term benefits. 
There are five possible mechanisms by which this increase of osteocalcin could be 
explained: first decreased elimination of osteocalcin by the kidney during etidronate ther-
apy. This is unlikely since in most studies on postmenopausal osteoporosis etidronate 
induces a decrease in osteocalcin. Secondly altered degradation, thirdly increased pro-
duction of osteocalcin, fourthly an indirect effect of etidronate on bone turnover by influ-
encing the inflammatory process [32] and fifthly initial displacement of osteocalcin from 
hydroxyapatite by EHDP as shown by Price et al in rats [33]. This could also explain the 
initial rise of osteocalcin found by Tobias et al in the first two weeks of treatment of 
postmenopausal women with HRT or a bisphosphonate [34]. 
A direct or indirect stimulatory effect of bisphosphonates on the osteoblast could be pos-
tulated especially in high turnover bone disease as in patients with Paget's disease, in 
whom an increase in osteocalcin occurs after APD treatment [35]. Also in vitamin D 
deficient postmenopausal osteoporotic women chronic etidronate therapy has been 
reported to induce a rise in osteocalcin [36]. Bisphosphonates may exert their effects on 
the osteoblast indirectly by at least two different mechanisms. One is the modulation in 
release of cytokines by the osteoclast and the release of local signals due to the effects on 
the osteoclast function, resulting in decreased resorption [37]. The other is through stim-
ulation of the production of the calciotropic hormones 1,25 dihydroxyvitamin D and 
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PTR, which could increase during bisphosphonate treatment [6,38,39]. Recently Staal et 
al [40] and Zhang et al [41] reported increased expression of plasma osteocalcin by 1,25 
OR vitamin D3 which is inhibited by glucocorticoids [42]. Our hypothesis is that 
etidronate could reverse this mechanism. Unfortunately we have no data on plasma 1,25 
vitamin D3 levels during the short term administration of glucocorticoid alone or com-
bined glucocorticoid and etidronate. During the short term treatment period, serum phos-
phate and PTR levels remained virtually unchanged in both groups. Therefore it seems 
unlikely that they trigger changes that could explain the increase in osteocalcin. Finally 
etidronate could have a direct stimulatory effect on osteoblast function in a state of glu-
cocorticoid induced high bone turnover. 
In conclusion the present study is the first demonstrating an acute beneficial effect of 
etidronate on glucocorticoid induced bone degradation as reflected by prevention of bone 
resorption and in addition stimulation of the bone formation marker osteocalcin by a thus 
far unknown direct or indirect effect (PTR, 1.25 OR D3 ) on the osteoblast. A study with 
more individuals, a longer follow-up period with new more specific markers and vitamin D 
metabolites is warranted. 
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THE PREVENTION OF GLUCOCORTICOID-
INDUCED OSTEOPOROSIS WITH ETIDRONATE 
IN POSTMENOPAUSAL WOMEN WITH 
TEMPORAL ARTERITIS 
H. Mulder, M.D. and A. Struys, M.D. 
(Published as; "Etidronate Prevents Steroid-Induced Bone Loss" in Br J Rheumatol 
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SUMMARY 
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We conducted a prospective study about the effect of etidronate on corticosteroid-
induced bone loss in postmenopausal women with temporal arteritis for whom high-dose 
prednisone therapy was indicated. Group A (n = 10) received etidronate (400 mg/day for 
2 weeks, then 11 weeks off etidronate; four cycles total) and prednisone; Group B (n = 
10) received only prednisone. Vertebral bone mineral density (BMD) was measured 
blinded by dual x-ray absorptiometry. 
At 3, 6 and 12 months, vertebral BMD was significantly (p < 0.01) increased in Group A and 
decreased in Group B, based on mean actual and percent changes in BMD and mean changes 
in BMD Z-score from baseline. Between-group comparisons were also significant (p < 0.002) 
at each time point. No adverse events related to etidronate treatment were reported. 
Our results suggest that instituting intermittent cyclical etidronate therapy when high-
dose prednisone therapy is begun may prevent corticosteroid-induced bone loss. Further 
research into bisphosphonate use in corticosteroid-induced bone loss (with larger patient 
populations, longer follow-up and fracture assessment) is wananted. 
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INTRODUCTION 
The concept that excess endogenous glucocorticoid can lead to an increased tendency to 
fracture was first described by Cushing in 1932 [1]. Soon after the introduction of corti-
sone as a therapeutic agent, it became clear that exogenous hypercortisolism was also 
deleterious to the skeleton [2]. Both bone quantity and bone quality are decreased with 
the use of corticosteroids. Prospective studies of bone mass during corticosteroid treat-
ment have confirmed that their use can cause progressive bone loss [2]. Data suggest that 
up to 50% of patients taking glucocorticoids long-term will develop osteoporosis and 
experience atraumatic fractures due to the resultant compromised bone quality [2-4]. 
The pathogenesis of corticosteroid-induced bone loss is associated with decreased bone 
formation and increased bone resorption [2]. Decreased intestinal calcium absorption and 
increased urinary calcium excretion are also attributable to corticosteroid use and con-
tribute to a negative calcium balance [2]. This negative balance in turn leads to sec-
ondary hyperparathyroidism that results in increased bone resorptive activity [2]. These 
effects are manifested by accelerated bone loss early in treatment (within the first 6-12 
months), followed by continuing losses and slower rates in subsequent years [2,5]. 
Although the effects of steroids on bone and calcium balance are well described, no fully 
safe and effective therapeutic or prophylactic regimen for corticosteroid-induced bone 
loss has been established. However, antiresorptive agents such as estrogen [6], calcitonin 
(given either parentally or nasally) [7], and the bisphosphonate pamidronate [8,9] have 
been reported to be effective in preventing or reversing corticosteroid-induced bone loss. 
In addition, the prophylactic use of calcitriol and calcium, with or without calcitonin has 
been shown to prevent corticosteroid-induced bone loss [10]. 
The bisphosphonate etidronate, given in an intermittent cyclical regimen, has been 
demonstrated to increase vertebral bone mass significantly and reduce the incidence of 
vertebral fractures in patients with postmenopausal osteoporosis [9,11]. The objective of 
the current study was to determine whether this antiresorptive agent, when administered 
in a similar manner and at the outset of corticosteroid therapy, could prevent the early 
accelerated bone loss associated with pharmacological doses of prednisone. 
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MATERIALS AND METHODS 
Study Design 
This study was conducted as a prospective I-year clinical trial according to the guide-
lines of the Helsinki declaration for physician-initiated studies. Patients were recruit-
ed from one investigation site (Usselland Hospital, the Netherlands) from April 15, 
1990 to February 1, 1991. The study enrolled postmenopausal women with a biopsy-
confirmed diagnosis of temporal arteritis for whom high-dose prednisone therapy was 
indicated. Patients were excluded from the study if they had any disease or were 
receiving any medication, with the exception of the study drugs, that would interfere 
with calcium or bone metabolism. A complete history and physical examination 
including routine haematology, serum chemistry, and urinalysis evaluations were per-
formed before treatment. 
Patients were alternately assigned to one of two treatment groups. Group A received 
intermittent cyclical oral etidronate dis odium 400 mg (Didronel®, Procter & Gamble 
Pharmaceuticals, Norwich, New York) once daily for 2 weeks, followed by 11 weeks off 
therapy (four cycles total) in conjunction with appropriate prednisone therapy. Group B 
received only prednisone therapy. The daily prednisone dosage in both groups was 60 
mg once daily for 4 weeks, followed by dose adjustment (decrease) to maintain an ery-
throcyte sedimentation rate (ESR) below 30 mm/hour. Patients had a daily dietary calci-
um intake of 400-800 mg; no supplemental calcium was administered. 
Assessment 
Vertebral (Ll-L4) bone mineral density (BMD) was measured by dual x-ray absorptiom-
etry (Hologic QDR 1000) at baseline and at 3, 6 and 12 months by a technician blinded 
to treatment assignment. Serum alkaline phosphatase (a biochemical marker of bone 
turnover) was measured at baseline and 12 months. Patients were judged eligible for 
evaluation if they followed the prescribed regimens and had the scheduled BMD deter-
minations during the 12-month study. 
Statistics 
Vertebral BMD data, serum alkaline phosphatase, and the respective actual and percent 
changes from baseline in these clinical variables are displayed as mean ± SEM. Statisti-
cal comparisons (Minitab, Release 5.1, Minitab, Inc., State College, Pennsylvania) were 
performed by one-sample t-tests for between-groups changes, respectively. Z-scores 
(comparing individual patients' BMD with the mean of BMD of age-matched normal 
women) were calculated at baseline and at 3,6 and 12 months; T-scores (comparing indi-
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vidual patients' BMD with the mean BMD of young normal women) were calculated 
only at baseline. Statistical significance was assigned as p < 0.05. Ninety-five percent 
confidence intervals (95% CI) were calculated by a two-sample t procedure. 
RESULTS 
Ten women received intermittent cyclical etidronate concurrently with the prescribed 
prednisone regimen (Group A); 10 women received only the prednisone regimen (Group 
B). The mean age of the patients receiving etidronate and prednisone treatment was 74 
years (range, 62-82 years), and the mean age of the control patients was 72 years (range 
58-84 years). Baseline BMD (Table I) was not statistically significantly different 
between the groups. At baseline, Z-scores were 0.00±0.33 in Group A and 0.21±0.20 in 
Group B (95% CI: -1.02,0.61); T-scores were -2.26±0.45 in group A and -1.80±0.32 in 
GroupB. 
Each of the patients responded to the prednisone therapy for temporal arteritis. Mean 
prednisone dosages of the 12 month study period were 11.0 mg/day in Group A and 10.7 
TABLEl 
Vertebral Bone Mineral Density 
Length of 
treatment 
Measurement (Months) Group A GroupB 95% cI' 
BMD (g/cm2) Baseline 0.798 ± 0.050 0.850± 0.035 -0.l80,0.076 
3 0.802 ± 0.050 0.829 ± 0.034 -0.155,0.l01 
6 0.807 ± 0.050 0.815 ± 0.033 -0.136,0.121 
12 0.809 ± 0.050 0.807 ± 0.032 -0.125,0.129 
Change from baseline (g/cm2) 3 0.005 ± 0.001 H -0.020 ± 0.002* 0.02,0.030 
6 0.009 ± O.003H -0.035 ± 0.004* 0.034,0.054 
12 0.011 ± O.003H -0.042 ± 0.006* 0.040,0.068 
Percentage change from 3 0.58 ± 0.14tl -2.36 ± 0.25* 2.33,3.57 
baseline (%) 6 1.l0±0.31H -4.09 ± 0.451 4.02,6.36 
12 1.42± 0.45H -4.95 ± 0.64* 4.71,8.03 
3 0.06±0.0I tl 0.01 ± 0.001 0.02,0,07 
Change from baseline (Z-score) 6 0.11 ± 0.02tt 0.10 ± 0.031 0.l4,0.29 
12 0.16± O.03H -0.15 ± 0.041 0.20,0.41 
Group A (N=10) received intermittent cyclical etidronate in conjunction with high-dose prednisone; 
Group B (N=1O) received high-dose prednisone only. Vertebral BMD. 
*95% CI applies to the difference between treatment groups and was calculated by a two-sample (-
f,rocedure. 
P <0.002, compared with Group B; two sample (-test. 
Ip <0.01, compared with baseline; one-sample (-test. 
THE PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 117 
mg/day in Group B. 
At 3, 6 and 12 months, vertebral BMD was significantly (P < 0.01) increased in Group A 
and decreased in Group B, based on mean actual and percent changes from baseline in 
BMD and mean changes from baseline in BMD Z -score (table I). Between-group com-
parisons were also significant (P < 0.002) at each time point. At 12 months, the mean 
percent change from baseline in BMD was + 1.42±0.4S% in Group A and -4.9S ±0.64% 
in Group B; the 9S% CI showed that the difference between the two treatment groups 
was at least 4.71 % and as much as 8.03%. Nine of the 10 patients treated with etidronate 
and prednisone had increases in bone mass, whereas all 10 patients treated with only 
prednisone had decreases (Fig.l). 
At 12 months, the change from baseline in serum alkaline phosphatase was 6.2±3.9% in 
Group A and -S.3±3.0% in group B (p < O.OS, between groups). No clinically significant 
changes in routine clinical and laboratory evaluations were noted. Etidronate was well 
tolerated, and no adverse events related to etidronate treatment were reported. 
DISCUSSION 
Our study demonstrated that intermittent cyclical etidronate can prevent the negative 
effects of continuous prednisone use on bone mass. The study patients were at high risk 
of developing osteoporosis, being elderly postmenopausal women requiring first-time 
high-dose prednisone treatment for 6 months or longer. The significant and progressive 
decreases from baseline in BMD in the group treated with prednisone alone confirmed a 
continued loss of bone mass induced by prednisone in excess of losses due to age or 
menopause. In contrast, the patients who received concurrent etidronate exhibited signif-
icant increases in bone mass that were comparable to those seen in studies of etidronate 
in the treatment of postmenopausal osteoporosis [11 ,12]. Significant increases from 
baseline in BMD Z-scores in this group further suggest a beneficial protection from or 
prevention of these progressive corticosteroid-induced and age-related losses in bone 
mass. This is especially important because of the recognised strong inverse relationship 
between low bone mass and an increased risk of atraumatic vertebral fractures [13]. 
Controversy currently exists about the overall influence of clinical factors (such as age, 
sex, underlying disease, dose, treatment duration etc.) on corticosteroid-induced bone 
loss. Studies in heterogeneous patient populations have shown variable results as to the 
contribution of these and other factors. However, because we studied a highly uniform 
population, the conclusions drawn from our results can be interpreted independent of 
other possibly confounding clinical influences. 
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Figure 1 
Percent change from baseline In vertebral BMD after twelve months of treatment with 
intermiitent cyclical etidronate in combination with high dose prednisone (N=lO) or high 
dose prednisone only (N=lO). Means are shown as horizontal bars. 
*p < 0.001. compared with high dose prednisone; two-sample t-test 
THE PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 119 
The result of this study of etidronate and those of Reid et al [8,9] in their study of another 
bisphosphonate, pamidronate, suggest that this class of antiresorptive drugs can counter-
act corticosteroid-induced bone loss by producing an overall increase in bone mass. It is 
also important to note that, in our study, etidronate treatment was initiated at the same 
time as the patients' first exposure to prednisone. This is in contrast with the Reid et al. 
investigations, in which all patients had already received long-term corticosteroid treat-
ment and likely experienced bone loss before pamidronate intervention was begun [8,9]. 
Our results suggest that instituting intermittent cyclical etidronate therapy as soon as 
high-dose prednisone therapy is begun can effectively prevent this drug-induced bone 
loss. However, because our study involved a limited number of patients and was restrict-
ed to only those with temporal arteritis, further studies to confirm the efficacy of bispho-
sphonates in corticosteroid-induced bone loss (i.e. with larger patient populations, longer 
follow-up, and assessment of fractures) is warranted. 
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INTERVENTION WITH ETIDRONATE IN PATIENTS 
WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
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(Published as "Cyclical Etidronate Reverses Bone Loss of the Spine and Proximal Femur in 
Patients with Established Corticosteroid-Induced Osteoporosis" in Am J Med1995; 99:235-242) 
SUMMARY 
The purpose of the study was to compare the bone-mass effects of calcium supplementa-
tion and intermittent cyclic etidronate in patients with established corticosteroid-induced 
osteoporosis. 
Eighteen male and 21 female patients who had established corticosteroid-induced osteo-
porosis and were receiving chronic prednisone therapy (> 10 mg/d) were emolled in a 
prospective 12-month, open-label study. In addition to continuing prednisone therapy, 
patients received continuous calcium supplementation 500 mg/d (n = 20) or four cycles 
of intermittent cyclic etidronate therapy consisting of etidronate 400 mg/d for 14 days, 
followed by calcium 500 mg/d for 76 days (n = 19). Bone mineral density (BMD) of the 
spine (Ll-L4) and proximal femur (total hip, femoral neck, trochanter, Ward's triangle) 
was measured by dual-energy x-ray absorptiometry (DEXA) at baseline, 6 months, and 
12 months by staff blinded to the treatment. Serum calcium, phosphorus, and alkaline 
phosphatase were also measured at the these times. 
Treatment with intermittent cyclic etidronate for 12 months resulted in significant 
increases of 5.7% and 6.8% in BMD of the spine and proximal femur (total hip), respec-
tively (p < 0.02 versus baseline; p < 0.001 versus calcium group). Calcium supplementa-
tion alone did not prevent significant losses of 3.4% and 4.1 % in BMD of those respec-
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tive sites (p < 0.02 versus baseline). Z scores at the end of study reflected significant 
increases in BMD of the spine and proximal femur (all regions) in the etidronate group 
(p < 0.01) and significant decreases at the spine, proximal femur, and trochanter in the 
calcium group (p < 0.01). After 12 months, the difference between the groups was 9.l % 
(p < 0.01; 95% CI: 6.3% to 11.9%) at the spine and 10.9% (p < 0.01; CI 7.8% to l4.l%) 
at the proximal femur (total hip). Seventeen (89%) of the etidronate-treated patients had 
increases in BMD of both skeletal sites, whereas only 2 (10%) and 3 (15%) of the cal-
cium-treated patients had positive changes in BMD of the spine and proximal femur 
(total hip), respectively (p < 0.01). Serum calcium, phosphorus, and alkaline phosphatase 
levels did not change significantly during the study in either treatment group. Both treat-
ment regimens were well tolerated, with no interactions between prednisone therapy and 
the study medications. Analyses of response by subgroups (female/male, pulmonary/non-
pulmonary) showed no significant attribute-dependent changes during the l2-month 
study. At baseline, women had significantly lower baseline BMD of the spine and proxi-
mal femur (total hip) (p < 0.01), and patients with pulmonary disease had significantly 
longer duration of prednisone therapy and cumulative prednisone dose (p < 0.03). 
We concluded that, intermittent cyclic etidronate reversed the progressive loss of bone 
mineral density of the spine and proximal femur in female and male patients with estab-
lished osteoporosis secondary to chronic corticosteroid (prednisone) therapy for pul-
monary and non-pulmonary diseases. Calcium supplementation alone did not prevent or 
attenuate these corticosteroid-induced losses. 
KEYWORDS 
Bone mass, calcium, corticosteroid, cyclic, etidronate, osteoporosis, prednisone, proxi-
mal femur, spine 
INTRODUCTION 
The osteoporosis and pathological fractures associated with prolonged therapy with cor-
ticosteroids have been recognised for over four decades. Corticosteroid-induced osteo-
porosis may result from two concomitant mechanisms of basic bone function: inhibition 
of bone formation through direct corticosteroid action on osteoblasts and increased bone 
resorption due to indirect enhancement of osteoclastic activity [1,2]. Corticosteroids also 
inhibit the absorption of calcium in the gut [3]. The resulting negative bone balance pro-
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duces bone loss, particularly at skeletal sites rich in trabecular (or cancellous) bone [4]. 
This bone loss is rapid in the first few months and seems to proceed at a slower rate after 
6 to 12 months on therapy [5]. 
The means for the prevention and treatment of corticosteroid-induced osteoporosis 
remain poorly investigated. Among the treatment modalities proposed for this serious 
medical condition are supplemental calcium at doses up to 1500 mg/d, administered with 
or without vitamin D and/or thiazide [2,6-8]; estrogen replacement therapy for post-
menopausal women who require prolonged corticosteroid therapy [9]; calcitonin 
[8,10,11]; bisphosphonates [12,13]; and fluoride [14]. Estrogen, calcitonin, and bisphos-
phonates are pharmacologically bone antiresorptive agents, and thus, their study in the 
clinic appears to have a rational basis. 
Controlled clinical studies of the bisphosphonates have shown that these agents can 
increase vertebral bone mass both in patients with postmenopausal (primary) osteoporo-
sis and in those with corticosteroid-induced (secondary) osteoporosis. In patients with 
established postmenopausal osteoporosis, an intermittent cyclic regimen of oral 
etidronate produced significant increases in bone mineral density of the spine and also 
reduced the rate of vertebral fractures [15-l7]. We also recently reported that a similar 
regimen of etidronate prevented vertebral bone loss when therapy was initiated at the 
same time as corticosteroid treatment [18]. In a study of oral pamidronate, patients with 
established corticosteroid-induced osteoporosis experienced a significant increase in ver-
tebral bone mineral density after 12 months of treatment [12]. Other investigators have 
also reported encouraging preliminary results in the treatment of established cortico-
steroid-induced osteoporosis with intermittent cyclic regimens with oral etidronate [19-
22] and an intermittent regimen with intravenous pamidronate [22]. 
We conducted a 12-month, prospective clinical study to compare the bone-mass effects 
of an intermittent cyclic etidronate regimen with those of calcium supplementation in 
patients with established corticosteroid-induced osteoporosis. The results presented in 
this report suggest that the intermittent cyclic etidronate regimen is an effective treatment 
for established corticosteroid-induced osteoporosis. 
PATIENTS AND METHODS 
This prospective open-label study was undertaken at a private internal medicine and 
endocrinology/metabolism ambulatory clinic. Patients with established corticosteroid-
induced osteoporosis were recruited from Rotterdam and the immediate environs during 
the I-year period beginning 1 November 1989. Corticosteroid-induced osteoporosis was 
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defined as a vertebral bone mineral density two standard deviations or more below mean 
peak bone mass for young normal subjects, i.e., T score::::; 2.0 SD. The patient dosing 
and observation period began 1 December 1989 and concluded 30 November 1991. 
To be eligible for study, patients must have been receiving chronic uninterrupted corti-
costeroid therapy for at least 1 year or have received a cumulative prednisone dose> 4.0 
gram, equivalent to at least 1 year of prednisone 10 mg/d. Patients were also in stable 
condition with regard to the primary corticosteroid-treated disease and in general good 
health, with no other metabolic bone disease or insulin-dependent diabetes mellitus. 
Patients were excluded if, within the year preceding the study, they had received calcium 
supplements of greater than 1000 mg/d, pharmacological doses of vitamin D or one of its 
metabolites, estrogen, calcitonin, bisphosphonates, or fluoride. Patients were alternately 
assigned to treatment groups according to their study eligibility (including informed con-
sent) and random appearance at the clinic. The procedures followed were in accord with 
guidelines of the Helsinki declaration for physician-initiated studies. 
Patients continued prednisone therapy and received either calcium supplementation 500 
mg/d as calcium citrate (Cacit® 500, Procter & Gamble Pharmaceuticals, Norwich, NY) 
or intermittent cyclic etidronate therapy (Didrokit®, Procter & Gamble Pharmaceuticals, 
Norwich, NY). The etidronate cyclic regimen (Didrokit) consisted of etidronate disodi-
urn 400 mg/d for 14 days, followed by calcium 500 mg/d (as calcium citrate) for 76 days; 
with a total of four repetitions of the cycle during the 12-month study. 
A complete history and physical examination, routine haematology, and multiphase 
serum chemistry were performed at study entry. Serum calcium, phosphorus, and alka-
line phosphatase were measured at baseline and at 6 and 12 months. 
Bone mineral density (BMD) (g/cm2) of the lumbar spine (expressed as the mean of the 
four vertebrae measured, LI-L4) and proximal femur (total hip, femoral neck, trochanter, 
and Ward's triangle) was measured by dual-energy x-ray absorptiometry (DXA; Hologic 
QDRlOOO, (Hologic Inc., Waltham MA) at baseline and at 6 and 12 months. Bone mass 
measurements were conducted at an independent clinical research organisation (Good 
Clinical Practice, Rotterdam, The Netherlands) whose staff was blinded to patient treat-
ment. The coefficient of variation of BMD measurements was 0,50%. 
Baseline demographic characteristics, expressed as mean ± standard deviation (SD), 
were tested for between-group interactions by analysis of variance. Vertebral and hip 
BMD measurements were displayed as mean ± standard error of the mean (SEM) for 
each treatment group. Normative BMD scores for each patient at each time point were 
calculated from the mean BMD and standard deviation for normal subjects provided by 
the DXA instrument manufacturer, with Z score representing the number of standard 
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deviations between a patient's BMD and the age-matched mean BMD and T score repre-
senting the number of standard deviations between a patient's BMD and the young nor-
mal mean BMD. Changes from baseline in BMD (g/cm2 and percentage) were calculated 
for each patient at each time point. Mean ± SEM for Z scores, T scores (reported at 
baseline only), and changes from baseline were then determined for each treatment 
group. Statistical comparisons within groups were performed by one-sample Student's t-
tests and between groups, by two-sample Student's t-tests using a statistical package for 
personal computers (Minitab, Release 5.1, Minitab, Inc., State College, PA). Ninety-five 
percent confidence intervals were calculated by a two-sample t procedure. Statistical sig-
nificance was set at p < 0.05. 
RESULTS 
Patient Characteristics 
The initial study population comprised 41 older adults. Two patients dropped out of the 
study before the 6-month visit, one in the calcium group because of the discontinuation 
of prednisone therapy and one in the etidronate group because of epigastric distress relat-
ed to the study drug; baseline data for these two patients are excluded. This report 
includes data only on patients who completed the study. 
Thirty-nine patients with a mean age of 64 years (range 38 to 88) completed the study, 
20 in the calcium group and 19 in the etidronate group. Nineteen (90%) of the 21 women 
enrolled in the study were postmenopausal, with a mean of 17.5 years since menopause. 
The mean duration of corticosteroid (prednisone) therapy was 6.0 years with a mean 
cumulative dose of 29.3 g. At the start of the study, the mean daily prednisone dose was 
10.8 mg. Mean (± SD) spine and proximal femur (total hip) BMD Z scores for the com-
pleted study population were -2.5 ± 0.12 and -l.9 ± 0.1, respectively, and mean T scores 
were -3.7 ± 0.12 and -3.1 ± 0.13, respectively. 
The baseline characteristics of the completed study population are presented by treatment 
group in Table I. At baseline, the two treatment groups were comparable in age, height, 
weight, ratio of female to male patients, duration of exposure to and cumulative dose of 
prednisone therapy before study entry, and spine and proximal femur (total hip) BMD. 
The diseases for which the study patients were receiving prolonged prednisone therapy 
are shown in Table II. Twenty-two of the 39 patients in the study had pulmonary dis-
eases (chronic asthma; chronic obstructive pulmonary disease). The treatment groups 
were comparable in the types of disease and the number of patients in both the pul-
monary and non-pulmonary disease categories. 
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TABLE I 
Demographic Characteristics, Prednisone Exposure, 
and Bone Mineral Density of Patients at Baseline 
Calcium Etidronate 
(N = 20) (N = 19) 
Demographic characteristics 
Age (y) 
Height (cm) 
Weight (kg) 
Female:male ratio 
Prednisone exposure 
Duration of exposure (y) 
Cumulative dose (g) 
Bone mineral density 
Spine (Ll-L4) 
glcm2 
Z-score* 
T-score" 
Percent of young 
normal mean 
Proximal femur (total hip) 
glcm2 
Z-score+ 
T-score+ 
Percent of young 
Normal mean 
64.6± 13.4 
165 ± 7.5 
68.9 ± 10.4 
13:7 
6.1 ± 4.8 
31.9 ± 26.5 
0.656±0.1l1 
-2.3 ± 0.69 
-3.7 ± 0.94 
61.7 ± 10.0 
0.647±0.099 
-1.7 ± 0.70 
-2.9 ± 0.83 
63.2± 9.6 
62.3±14.5 
168 ± 10.5 
73.3±13.3 
8:11 
5.9 ±2.5 
26.6±9.8 
0.656±0.142 
-2.7 ±0.84 
-3.8 ± 1.16 
61.0±12.3 
0.609±0.120 
-2.2 ±0.65 
-3.4 ±0.76 
59.2±9.0 
Data reported as mean ± standard deviation unless othenvise indicated. 
+Z-score, bone mineral density normalised to age-matched mean; T-
score, bone mineral density normalised to young normal mean. 
TABLE II 
Diseases Requiring Chronic Corticosteroid 
Treatment in Study Population 
Disease Category 
Pulmonary" 
Non-pulmonary 
Gastrointestinalt 
Cardiovascular* 
Other§ 
Total 
Calcium Etidronate Total 
12 10 22 
5 5 10 
2 2 4 
1 2 3 
20 19 39 
Data reported as number of patients. 
• Asthma, chronic obstructive pulmonary disease. 
tCrohn's disease, chronic hepatitis, ulcerative colitis. 
*Giant cell arteritis. 
§Hemolytic anemia, polychondritis, thrombocytopenia. 
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TABLEm 
Changes in Bone Mineral Density of the Spine and Proximal Femnr (Total lfip) 
After Treatment With Calcinm or Intermittent Cyclic Etidronate 
Absolnte Values (gIcm') Percent Change from 
Spine 
Calcium 
Etidronate 
Proximal femur (total hip) 
Calcium 
Etidronate 
N Baseline (glcm') 
20 
19 
20 
19 
0.656 ± 0,025 
0.656 ± 0.032 
0.647 ± 0.022 
0.609 ± 0,028 
Data reported as mean ± standard error of the mean. 
'p <0.02 compared with baseline. 
Ip <0.001 compared with calcium group. 
6 Months 
0.642 ± 0.023' 
0.672 ± 0.031'1 
0.637 ± 0.022' 
0.635 ± 0.027'1 
TABLE IV 
Baseline 
12 Months 6 Months 12 Months 
0.633 ± 0.023' -2.0 ± 0.6' -304 ± 0.7' 
0.689 ± 0.030'1 2.7 ± 0.6'1 5.7 ± l.2'1 
0.620 ± 0.021' -1.5 ± 0.6' -4.1 ± 0.7' 
0.648 ± 0.027'1 4.6 ± 1.0'1 6.8 ± 004'1 
Changes in Bone Mineral Density of the Spine and Proximal Femur (Total lfip) After Treatment 
With Calcium or Intermittent Cyclic Etidronate: Characterisation According to Sex 
Calcium 
Skeletal Site Baseline (glcm') (N) 
Spine 
Female 0.620 ± 0.030 (13)' 
Male 0.722 ± 0.035 (7) 
Proximal femur (total hip) 
Female 0.638 ± 0.033 (13) 
Male 0.665 ± 0.Dl5 (7) 
Data reported as mean ± standard error of the mean. 
'p <0.05 compared witil men. 
t P <0.02 compared with baseline. 
j P <0.01 compared with calcium group. 
1 p <0.05 compared with baseline. 
% Il from Baseline 
6 Months 12 Months 
-2.5 ± 0.81 -3.6 ± 0.91 
-1.1 ± 0.51 -3.2 ± 1.1 t 
-1.6 ± 0.8 4.6 ± 0.91 
-1.5 ± 0.7 -3.3 ± LOt 
TABLE V 
Etidronate 
% Il from Baseline 
Baseline (gIcm') (N) 6 Months 12 Months 
0.545 ± 0.018 (8)' 3.9± l.2 t1 8.1 ± l.8t1 
0.732 ± 0.040 (11) 1.9 ± 0.6 t1 3.9 ± IAtI 
00494 ± 0.019 (8)' 6.1 ± l.2 t1 8.7 ± 2.611 
0.693 ± 0.023 (11) 3.5 ± l.3 t1 504 ± 1.411 
Changes in Bone Mineral Density of the Spine and Proximal Femur (Total lfip) After Treatment With Calcium or 
Intermittent Cyclic Etidronate: Characterisation According to Disease Category 
Calcium 
Skeletal Site Baseline (gIem') (N) 
Spine 
Pulmonary 0.633 ± 0,025 (12) 
on-pulmonary 0.690 ± 00490 (8) 
Proximal femur (total hip) 
Pulmonary 0.618 ± 0.024 (12) 
Non-pulmonary 0.692 ± 0.038 (8) 
Data reported as mean ± standard error of the mean. 
'p <0.02 compared with baseline. 
t P <0.01 compared witil calcium group. 
j p <0.05 compared with baseline. 
% Il from Baseline 
6 Months 12 Months 
-2.0 ± 0.6' -3.6 ± 0.8' 
-2.1 ± 1.2 -3.3 ± 1.41 
-1.2 ± 0.8' -3.5 ± 0.9' 
-2.0 ± 0.81 -5.1 ± 0.8' 
Etidronate 
% Il from Baseline 
Baseline (gIcm') (N) 6 Months 12 Months 
0.653 ± 0.041 (10) 1.5 ± 004'1 3.8 ± 104'1 
0.659 ± 0.054 (9) 4.1 ± 1.1'1 7.7 ± 1.8'1 
0.575 ± 0.033 (10) 6.2 ± 1.5'1 9.2 ± 2.1'1 
0.647 ± 0.044 (9) 2.9 ± 0.9't 4.1 ± 1.4'1 
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The subgroups of women and men differed significantly with respect to height (mean ± 
SD, 162.5 ± 7.4 cm versus 17l.3 ± 8.9 cm; p < 0.01), weight (67.3 ± 8.3 kg versus 75.4 
± 14.2 kg; P < 0.05), baseline BMD (0.592 ± 0.10 g/cm2 versus 0.731 ± 0.12 g/cm2; p 
< 0.01) and T score (- 4.14 ± 0.87 versus - 3.27 ± 1.04; p < 0.01) of the spine, and base-
line BMD of the proximal femur (total hip) (0.583 ± 0.12 g/cm2 versus 0.682 ± 0.07 
g/cm2; p < 0.01). They were comparable with respect to all other characteristics (data not 
shown). 
The subgroups of patients with pulmonary disease and those with non-pulmonary disease 
were significantly different with respect to duration of exposure to prednisone (mean ± 
SD, 7.1 ± 4.0 years versus 4.6 ± 2.9 years, respectively; p < 0.03) and cumulative pred-
nisone dose (35.0 ± 22.7 g versus 22.0 ± 13.6 g; P < 0.03). They were comparable with 
respect to all other characteristics (data not shown). 
Bone Mineral Density 
Treatment with intermittent cyclic etidronate regimen for 12 months resulted in signifi-
cant increases of 5.7% and 6.8% from baseline in BMD of the spine and proximal femur 
(total hip), respectively (p < 0.02). Calcium supplementation alone did not prevent sig-
nificant corticosteroid-induced losses of 3.4% and 4.1 % from baseline in BMD of those 
respective sites (p < 0.02) (Table III; Figure 1). The changes from baseline in the 
etidronate group differed significantly from those in the calcium group after both 6 and 
12 months of study (p < 0.001). After 12 months, the difference between the groups was 
9.1 % (95% CI 6.3% to 11.9%; P < 0.01) at the spine and 10.9% (95% CI 7.8% to 
14.1 %; p < 0.01) at the proximal femur (total hip). 
The changes from baseline in Z scores of the spine and proximal femur (total hip) were 
comparable within each treatment group after 12 months (mean ± SD, etidronate group: 
0.34 ± 0.06 and 0.34 ± 0.06, respectively; calcium group: - 0.17 ± 0.04 and - 0.19 ± 
0.04, respectively) (Figure 2). The mean changes in Z score of the spine and proximal 
femur (total hip, femoral neck, trochanter, and Ward's triangle) regions were significant-
ly different between treatment groups (p < 0.01). The changes in BMD Z score of these 
skeletal sites were uniformly positive in the etidronate group and uniformly negative in 
the calcium group. 
A significantly higher proportion of patients in the intermittent cyclic etidronate group 
had increases from baseline in BMD of the spine and proximal femur (total hip) after 12 
months of treatment (p < 0.01) (Figure 3). Seventeen (89%) of 19 etidronate-treated 
patients had increases in BMD of both skeletal sites, whereas only 2 (10%) and 3 (15%) 
of the calcium-treated patients experienced positive changes at the spine and proximal 
femur (total hip), respectively. 
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Figure 1. Mean (± SEM) percent change from baseline in bone mineral density 
ofthe spine (L1_L4) and proximal femur (total hip) during 12 
months of treatment with calcium (n = 20; open circles) or 
intermittent cyclic etidronate (n = 19; solid circles). >I< p <0.02 
compared with baseline; t p < 0.001 compared with calcium group. 
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Figure 2. Mean (± SEM) in Z score from baseline in bone mineral density of the spine 
(Ll_L4) and proximal femur (total hip, femoral neck, trochanter, and Ward's 
triangle) after 12 months of treatment with calcium (n = 20; open bars) or 
intermittent cyclic etidronate (n = 19; solid bars). * p <0.01 compared with 
baseline; t p < 0.01 compared with calcium group. 
Analyses of response by subgroups (female/male, pulmonary/non-pulmonary) showed no 
significant attribute-dependent changes. Women and men did not differ significantly in 
the extent of corticosteroid-induced bone loss or the response to etidronate treatment dur-
ing the study period (Table IV). Not surprisingly, women had significantly lower base-
line BMD of the spine than men in both treatment groups (p < 0.05); baseline BMD of 
the proximal femur (total hip) was significantly lower in women in the etidronate group 
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proximal femur (total hip) in individual patients after 12 months of treatment with 
calcium (n = 20; open circles) or intermittent cyclic etidronate (n = 19; solid circles), 
Horizontal bars mark mean values, • p <0,02 compared with baseline; t p < 0,001 
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(p < 0.01). Corticosteroid-treated patients with pulmonary disease and those with non-
pulmonary disease also had comparable responses to calcium supplementation (losses in 
BMD) and to etidronate treatment (increases in BMD) at the spine and proximal femur 
(total hip) (Table V). 
Serum calcium and phosphorus and haematological indices remained stable in both 
groups during the study period (data not shown). Serum alkaline phosphatase, a clinical-
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ly useful marker of bone remodelling, did not change significantly after 6 and 12 months 
of treatment with calcium (mean change: 0.2% and 0.9%, respectively) or etidronate 
(0.1 % and - 3.9%, respectively). 
Side Effects 
Both treatment regimens were well tolerated. There were no untoward reactions, unex-
pected side effects, or toxicity attributable to either treatment. One patient in the 
etidronate group dropped out of the study because of epigastric distress. No clinically 
apparent interactions were observed between corticosteroid treatment on the primary dis-
ease and the study medications. 
DISCUSSION 
The results of this study demonstrate the ability of intermittent cyclic etidronate to 
reverse progressive bone loss in the spine and proximal femur in patients with estab-
lished corticosteroid-induced osteoporosis. In the entire popUlation and the subgroups 
studied (women and men, pulmonary disease and non-pulmonary disease), intermittent 
cyclic etidronate therapy for 12 months produced significant increases in BMD of the 
spine and proximal femur (total hip), as compared both with baseline and with the calci-
um group (p < 0.02). The gains in bone mass in the etidronate group were similar at the 
two skeletal sites, with mean changes of about 6 to 7% in BMD and mean changes of + 
0.34 in BMD Z score. 
The effects of etidronate on BMD of the spine in our study are comparable to those 
repOlted for other bone antiresorptive agents tested for prevention of bone loss in early 
corticosteroid treatment [8,11] and established corticosteroid-induced osteoporosis asso-
ciated with chronic treatment [9,13]. However, the positive effects of intermittent cyclic 
etidronate on BMD of the proximal femur (total hip) are, to our knowledge, the first 
reported for a therapeutic agent at this clinically important skeletal region. A recent clini-
cal study in which treatment with calcitriol alone or in combination with calcitonin was 
concurrently initiated with corticosteroid therapy reported effectiveness in the prevention 
of bone loss in the lumbar spine but not in the femoral neck [23]. A recent review of clin-
ical studies of the treatment of corticosteroid-induced osteoporosis or early bone loss [1] 
included no data for bone mass of the proximal femur, most likely because the studies 
were conducted when instruments for the accurate assessment of bone mass of the hip 
were not available. 
The similarity we observed in the degree of change in BMD Z score at the spine and 
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proximal femur (total hip) after 12 months of treatment has important clinical implica-
tions. The inverse relationship between bone mass and the risk of spinal and hip fractures 
in osteoporosis is well recognised [23-26]. Although this relationship can predict hip 
fractures from BMD measurements at most skeletal sites [25,26], Cummings et a1. [26] 
found the bone mass of the proximal femur to be the strongest predictor of hip fractures. 
A decrease in BMD of the proximal femur (total hip, femoral neck, trochanter, or Ward's 
triangle) by one standard deviation increases the relative age-adjusted risks of hip frac-
tures by about threefold. In epidemiological studies, Ross et al. have also estimated simi-
lar increases in the risk of spinal fracture for each standard deviation (age-matched) 
decrease in BMD of the spine [23]. Maintenance of bone mass at these two sites is there-
fore clinically prudent, especially in postmenopausal women and other patients at risk for 
primary osteoporosis for whom chronic moderate- to high-dose corticosteroid therapy is 
ongoing or planned. In our study, the group of patients who received only calcium sup-
plementation had pre-existing compromised bone mass of the spine and proximal femur 
(total hip), with Z scores of - 2.3 SD and - 1.7 SD, respectively (Table I), and subse-
quently lost bone mass equivalent to an additional - 0.17 and - 0.19 standard deviations 
during the 12-month study period. The group of patients who received intermittent cyclic 
etidronate treatment had comparably low bone mass of the spine and proximal femur 
(total hip) at baseline, with Z scores of - 2.7 SD and - 2.2 SD, respectively (Table I), but 
in contrast gained bone mass equivalent to + 0.34 standard deviation at both skeletal 
sites. The resulting difference between the calcium and etidronate groups in BMD of the 
spine and total hip at the end of the study was approximately half of a standard deviation 
(i.e., a 0.5 SD change in Z score). The relationship between changes in bone mass 
(expressed as increments of standard deviation) and the risk of fracture is exponential 
[23]. Thus, the potential for reductions in fracture risks as a result of these effects of 
etidronate treatment could be substantial and clinically significant. 
Corticosteroids have been previously reported to have different effects on the bone mass 
of different skeletal regions, that is, the axial skeleton (e.g., lumbar spine), which is pre-
dominantly trabecular or cancellous bone, and the appendicular or peripheral skeleton 
(e.g., radius or forearm, hip), which is predominantly cortical bone [3,28-30]. However, 
more recently, Sambrook et al. [27] observed comparable losses in bone mineral density 
of the spine and hip (femoral neck, trochanter, and Ward's triangle) in patients receiving 
either acute or chronic corticosteroid therapy. Our results are consistent with those find-
ings, with comparable corticosteroid-induced bone loss occurring in the spine and proxi-
mal femur (total hip) in the calcium-treated group after 12 months of study (Figure 2). 
Corticosteroid-induced bone loss has also been reported to occur at a higher rate and to 
be more substantial during the first 6 to12 months of corticosteroid therapy as compared 
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with subsequent losses, which occur at a much slower rate and may be negligible [2,5]. 
In another study from our clinic [18], postmenopausal women with temporal arteritis 
experienced a loss of 5.0% in bone mineral density of the spine in the first year of pred-
nisone therapy (mean daily dose: 10.7 mg). In the current study, long-term prednisone 
therapy (range of duration: 1-18 years) had already resulted in moderately advanced bone 
loss in our patients, as evidenced by the mean BMD Z scores for the spine (- 2.5 SD) and 
proximal femur (total hip) (- 1.9 SD). However, we continued to observe relatively high 
rates of bone loss in the calcium-treated patients, with mean changes of - 3.4% in BMD 
of the spine and - 4.l % in BMD of the proximal femur during the l2-month study (Table 
III). The results of both studies confirm that chronic, continuous corticosteroid adminis-
tration of 10 mg/day or more substantially affects skeletal bone mass. This underscores 
the need to maintain chronic corticosteroid doses at the lowest levels necessary for thera-
peutic effects, since corticosteroid-induced bone loss has been reported to be less likely 
at daily doses of less than 7.5 mg [1]. However, in patients whose clinical conditions 
require chronic corticosteroid therapy at daily doses of at least 10 mg of prednisone (or 
its equivalent), therapeutic intervention to prevent or attenuate bone loss should be con-
sidered. 
In our study, intermittent cyclic etidronate reversed losses in bone mass of the spine and 
proximal femur in a majority of female and male patients with established osteoporosis 
secondary to chronic corticosteroid therapy for pulmonary and non-pulmonary diseases. 
Calcium supplementation alone did not prevent or attenuate the sustained bone loss at the 
spine and proximal femur that was associated with long-term continuous corticosteroid 
therapy. Controlled, blinded studies are needed to confirm the encouraging results of this 
study of intermittent cyclic etidronate in the treatment of corticosteroid-induced osteo-
porosis. 
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GENERAL DISCUSSION 
1. NEW HYPOTHESIS AND ANIMAL MODELS IN THE PATHOPHYSIOLOGY 
OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
Bone loss is one of the major side effects of glucocorticoid treatment. Histologically glu-
cocorticoid-induced osteoporosis is characterised by a decreased bone formation rate, 
decreased wall thickness of trabeculae and increased bone resorption (see chapter 1). 
Increased bone resorption, decreased osteob1asts proliferation and biosynthetic activity, 
sex hormone deficiency, as well as hyperparathyroidism resulting from decreased intesti-
nal calcium absorption and hypercalciuria due to altered vitamin D metabolism, all have 
been proposed as mechanisms for the loss of bone that ensues with glucocorticoid excess 
[1]. However, none of these mechanisms provides a satisfactory explanation for the car-
dinal histological features of glucocorticoid-induced osteoporosis and the evidence to 
support these mechanisms appeared to be weak and conflicting (see chapter 1). Therefore 
continuing research is necessarily to clarify the pathophysiological mechanisms of gluco-
corticoid-induced osteoporosis. Weinstein et al recently presented new insights in the 
pathofysiology of glucocorticoid-induced osteoporosis by using the mouse as a model. 
They claimed that the mouse, unlike the rat and other previously examined laboratory 
animals, is a faithful animal model of glucocorticoid-induced bone loss in humans. They 
reported that, after only 7 days of treatment, the same histomorphometric changes, seen 
in biopsies from patients receiving long-term glucocorticoid therapy, could be observed 
in mice [2]. They suggest that decreased production of osteoclasts can explain the reduc-
tion in bone turnover with chronic glucocorticoid excess, whereas decreased production 
and apoptosis of osteoblasts can explain the decline in bone formation and trabecular 
width. According to these authors, increased apoptosis of osteocytes is also involved in 
the pathofysiology of glucocorticoid-induced osteoporosis. These cells embedded in the 
bone matrix are suggested to playa role in the detection of micro-damage and the subse-
quent transmission of the signal that leads to repair by remodelling [3]. This animal 
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model could be useful in further research, studying new therapies like anabolic agents 
(PTH) and/or inhibitors of bone resorption. 
II. BONE MINERAL MEASUREMENTS: WHAT TO DO? 
In the prevention study we measured only lumbar spine BMD. We now know that DXA 
measurement both at the lumbar spine and femoral neck are indicated in glucocorticoid 
treated patients. Especially in our first study, we should have performed scans of the 
femoral neck because measurements of the lumbar spine may be unreliable due to age-
related degenerative changes like osteophytes, osteochondrosis, decreased disk space and 
aortic calcifications. 
BMD measured by DXA can be expressed in different ways. In all studies we expressed 
our results as an areal density (g/cm2). For comparison with age- and sex-matched con-
trols we also used Z-scores to underscore the fact that we regard glucocorticoid-induced 
osteoporosis as a secondary form of osteoporosis. The use of T-score results in an over-
estimation of the effect of age, especially in elderly subjects. 
During the period our studies were performed, the field of bone densitometry has devel-
oped rapidly and many non-invasive techniques are currently available for clinical use. 
Especially three techniques are now widely used: DXA, QCT, QUS. 
The DXA technique makes it possible to quantify the amount of bone in the lumbar 
spine, proximal femur, forearm or entire skeleton with minimum radiation exposure and 
with high degree of accuracy and precision. However, as discussed earlier, with DXA 
bone mass is expressed as an areal density. Therefore collapse of one or more vertebral 
bodies in the region of interest can lead to falsely increased BMD values. Furthermore it 
is also impossible to differentiate between cortical and trabecular bone. Also osteophytes 
and aortic calcifications could lead to a false increase in BMD. To avoid this problem 
other scanning positions have been proposed. Using lateral scanning of the lumbar spine, 
the posterior processes of the vertebral body are excluded from the measurement, with 
the potential advantage that it provides a better insight in changes in trabecular bone [4]. 
However lateral scans of the vertebral bodies, particularly in the decubites position, are 
significantly less precise than AP scans. Furthermore the window for this technique is 
limited in case of deformities of especially lumbar vertebrae. 
QCT is also a precise and accurate method of measuring bone mass, with the major 
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advantage that a volumetric density is measured instead of an areal density. Another 
advantage, is the possibility to differentiate between cortical and trabecular bone. A rela-
tively disadvantage is the high radiation exposure, its lower availability and the impossi-
bility to measure hip BMD. 
QUS is a more recent development. It variously examines the velocity, attenuation or 
reflection of ultrasound. The interest in its use is that it does not involve ionising radia-
tion and may give some information concerning the structural organisation of bone in 
addition to bone mass. However, this technique needs additional study both with respect 
to the diagnosis and follow-up of treatment of patients with osteoporosis. 
The frequency of fractures in glucocorticoid-treated subjects suggests that physicians 
should be more aware of the devastating effects of glucocorticoids on the skeleton. Bone 
mineral density measurements provide an opportunity to quantify this effect. At present 
mostly T-scores are used to express BMD results. However it is important to realise that 
both T- and Z-scores reflects different forms of information which might effect the ulti-
mate actions taken in patient with glucocorticoid-induced osteoporosis. With respect to 
glucocorticoid-induced osteoporosis it remains questionable whether the T-score is the 
appropriate way to express and define this kind of osteoporosis. Given the fact that glu-
cocorticoid-induced osteoporosis is a secondary form of osteoporosis a Z score seems 
more appropriate. Of course interpretation can be combined with T -scores, to get insight 
in the age-related component of osteoporosis. 
Currently, it is still difficult to identify the individuals at risk. The use of the computer 
program, as described in chapter 5, might provide a tool to identify subjects on long-term 
maintenance treatment with glucocorticoids. This instrument could also be useful to 
recruit populations to study in more detail the relationship between BMD and fracture in 
glucocorticoid-treated patients. 
Taken together, the fact that glucocorticoids mostly effect trabecular bone has conse-
quences for the interpretation of BMD results. Furthermore, when interpreting the 
changes in bone one need to distinguish between effects due to the disease itself and 
those that are caused by glucocorticoid treatment. Another aspect of interest are potential 
differences in the response of QUS versus BMD parameters in subjects with glucocorti-
coid-induced osteoporosis. Since QUS parameters and BMD might provide different 
forms of information (chapter 2), combination of these techniques could be a valuable 
option for the future. Further studies on this area have to be awaited and till then QUS 
should not be used in daily clinical practice to diagnose and follow-up patients with glu-
cocorticoid-induced osteoporosis. 
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In conclusion: 
- DXA of lumbar spine and hip are still the best way to quantify glucocorticoid-induced 
osteoporosis 
- A combination of T - and Z- scores should be used in expressing BMD results 
- Whether a Z score below -1 SD and T-score below -1.5 SD are real cut-off points for 
treatment needs further study. 
- QUS should only be used as an experimental option in glucocorticoid-induced osteo-
porosis 
III. INHALED CORTICOSTEROIDS: FROM GOOD TO BAD? 
Over the past years, glucocorticoids have become established as a cornerstone of treat-
ment of asthmatic patients, because of their demonstrated clinical efficacy. However the 
indications and duration of use are not so well defined. It is clear that glucocorticoids 
should be given in the lowest possible dose. This is not only the case in oral glucocorti-
coids but also in case inhaled glucocorticoids are used. The studies on the effects of 
inhaled glucocorticoids on BMD are not conclusive. In our own study we reported a 
decrease in BMD. This was expected because different studies reported a decrease in 
markers of bone formation (chapter 3). However, not every patient using inhaled gluco-
corticoids is at risk. Grassi et al divided them in three groups: 
- "Low risk", inhaled budesonide less than 800 microgram a day 
- "Moderate risk", inhaled budesonide more than 800 microgram a day 
- "High risk", inhaled glucocorticoids combined with courses of oral glucocorticoids 
more than four times a year. 
Till now the absence of knowledge on the relation between duration, dose and device of 
inhaled glucocorticoids used and fracture risk must lead to a restrictive use of these 
drugs. Nevertheless the effects of inhaled glucocorticoids on bone mass in asthmatic 
patients are much smaller compared to oral glucocorticoids. Therefore we should use 
them if indicated, for a short period of time, at the lowest possible dose and with instruc-
tions to prevent ingestion. Studies combining data about, bone mass, fracture risk, dose 
and duration of inhaled glucocorticoids, device used and underlying disease are urgently 
needed. By adjusting our computer program for patients taking inhaled glucocorticoids, 
also these patients could be identified. 
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IV. TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 
Calcium, vitamin D and its metabolites, thiazide diuretics, fluoride, estrogen, testos-
terone, medroxyprogesterone, nandrolone decanoate, growth hormone, deflazacort, calci-
tonin and bisphosphonates have all been proposed as therapy for glucocorticoid-induced 
osteoporosis. Based on our data concerning BMD and the more recent data about frac-
ture risk, bisphosphonates are the only therapeutic options with "proven" fracture reduc-
tion and must, therefore considered as the first choice in the prevention and treatment of 
glucocorticoid-induced osteoporosis. Are other therapeutic options become worthless? 
Especially in glucocorticoid-induced osteoporosis, vitamin D induced calcium absorption 
is decreased due to the mechanisms described in chapter 1. Data reported by Koster et al 
showed that calcium or vitamin D deficiency decreased the efficacy of a bisphosphonate 
[5]. Therefore, calcium and vitamin D are a prerequisite for any therapy concerning 
osteoporosis. If we take a closer look at the studies that reported fracture reduction, it 
appeared that the control and treatment group both received calcium and vitamin D sup-
plements. So the first line of this paragraph could better be: "Combined therapy of bis-
phosphonates with vitamin D and calcium can be considered as the first choice in pre-
vention and treatment of glucocorticoid-induced osteoporosis". 
Combination of different treatment modalities and target specific glucocorticoids are 
future treatment options that needs further study. Given the decreased bone formation 
and the increased resorption in glucocorticoid-induced osteoporosis a combination of a 
stimulator of bone formation with an inhibitor of bone resorption seems to be a logical 
therapy. A potential stimulator of bone formation is PTH. Our own data suggested that 
the combination of magnesium with etidronate, in women with low serum magnesium, 
increased bone mass more than etidronate alone. [6]. This extra gain in bone mass can be 
explained by the increase in PTH when magnesium is added in those patients. A recent 
study with PTH and HRT showed spectacular results on BMD [7]. From other studies it 
appeared that prevention of osteoblast and osteocyte apoptosis is the principle mecha-
nism for the anabolic effect of PTH on bone [8,9]. Therefore, it seems that PTH and, per-
haps in the future PTH mimetics represent a rational therapy especially in glucocorti-
coid-induced osteoporosis. The reduction in fracture rate has to be awaited, as an 
increase in BMD will not always reflect a decrease in fracture risk, as shown in the case 
of fluoride [10,11]. Also the longterm safety of PTH is still unclear. However the combi-
nation of bone formation stimulators with anti-resorptive compounds like bisphospho-
nates is certainly an option which deserves further study. 
From the recent studies with risedronate and alendronate the numbers needed to treat 
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have been calculated. It was suggested that less than 10 percent needed to be treated for 
one year to prevent one vertebral fracture. If this is true this makes bisphosphonates a 
potential cost-efective treatment of ClOP [12]. 
HRT still have a prominent place in all guidelines. However, the question remains if 
HRT has the same beneficial effects in glucocorticoid-induced osteoporosis as it has in 
early postmenopausal osteoporosis. The efficacy and safety is still disputable and no evi-
dence on fracture reduction is provided (see chapter 4). Therefore the main indication for 
using HRT in CIOP should be limited to proven hypogonadism. Adler [13] stated that all 
patients with glucocorticoid-induced hypogonadism should be considered for sex hor-
mone replacement therapy. He advises to measure serum oestradiol in premenopausal 
women and testosterone in men, to determine which patients are functionally hypogo-
nadal. Nevertheless, HRT can be considered in the first years after menopause as second 
choice after bisphosphonates. 
Deflazacort -an oxazoline derivate of prednisone- is discussed in chapter 4 and seems 
not to be a well-validated option in the reduction of glucocorticoid-induced bone loss. 
Recently new "designer glucocorticoids" have been developed that exhibit anti-inflam-
matory activity in vivo as potently as classical glucocorticoids, without requiring gluco-
corticoid receptor-DNA binding and transactivation which could be the signal for cell 
apoptosis [14,15]. Further studies on these drugs have to be awaited. 
V. SUGGESTIONS FOR FURTHER RESEARCH 
In this dissertation we have presented data, about the use of etidronate in the prevention 
and treatment of glucocorticoid induced osteoporosis. Meanwhile these results have been 
confirmed by others using other bisphosphonates and also data have been obtained which 
support fracture reduction. The question "Who and When to Treat" remains prominent. 
Therefore, prospective studies are needed to identify better tools to select those subjects 
at highest risk for glucocorticoid-induced osteoporosis. Furthermore, we have to put 
more effort in the design of model systems to understand the pathophysiological mecha-
nisms underlying glucocorticoid-induced osteoporosis. In this respect the mouse model 
developed by Weinstein et al is promising and certainly deserves further study. Only the 
exact description of factors involved in the development of glucocorticoid-induced 
osteoporosis will provide the insights necessary to design new strategies to prevent and 
treat this devastating disease. 
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SUMMARY 
Osteoporosis is a serious adverse event caused by the use of glucocorticoids. The impact 
of fractures of hip and vertebral body on the individual is superimposed on the already 
compromised quality of life due to the underlying disease for which glucocorticoid treat-
ment was initiated. Also the cost of health care generated by these patients and the loss 
of economical productivity should be a challenge for the medical profession to find not 
only a solution for intervention strategies but also to create a signalling system to identi-
fy the patient at highest risk. 
The impact of glucocorticoids on bone and the consequences for the patient are often 
underestimated or not recognised by the medical profession. Research by and education 
of, this medical profession has to be done to provide a safety net for those who needs 
glucocorticoids for their daily living. This thesis provides a compact overview about 
pathofysiology, treatment, past, present and future research in the field of glucocorticoid-
induced osteoporosis. 
Chapter 1 focuses on the pathofysiology of glucocorticoid-induced osteoporosis. It pro-
vides an overview of the literature on the effects of glucocorticoids at the cellular and 
skeletal level and describes the different pathophysiological mechanisms involved. 
Chapter 2 describes the risk of fracture in patients treated with glucocorticoids. The 
assessment of risk is complicated because it consists out of many, sometimes indepen-
dent components. The division in skeletal and non-skeletal components is the most logi-
cal one, however interactions between both components is complex and makes it difficult 
to clearly define prediction rules. BMD plays an important role in the skeletal component 
of fracture risk and the different methods of BMD measurements are discussed. 
Chapter 3 gives an overview about the impact of inhaled glucocorticoids on calcium and 
bone homeostasis. The literature and the data provided appeared to be inhomogeneous 
and difficult to interpret. Inhaled glucocorticoids appeared to have less systemic adverse 
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events but in higher dosages it still has to be regarded as a risk factor for developing 
steroid-induced osteoporosis. 
Chapter 4 gives an overview of the literature about the different treatment modalities 
and their rationale. It appeared that the combination of vitamin D, calcium and bisphos-
phonates is the only proven combination to reduce fractures in glucocorticoid-induced 
osteoporosis. 
Chapter 5 describes the results of a search, using population based databases of general 
pharmacists, by a special designed computer program. 
Twenty-two large population based databases from general pharmacists, randomised 
throughout the Netherlands were screened. The investigated population consisted of 
248,169 people. This population consisted out of 157.461 subjects with a public insur-
ance and 90.708 subjects with a private insurance. The age-specific prevalence of long-
term prednisone use, was calculated in the population with a public insurance. An age-
related increase of prednisone use was observed from 0.015% at the age of 0-10 yrs up to 
the highest prevalence (1.4%) in the age-group 80-89 yrs (overall prevalence of 0.27%). 
Nine-hundred sixty-four patients (532 women and 432 men, aged 4-98 years) receiving 
long-term prednisone (7.5 mg prednisone daily for ~ 3 months), and thereby at risk for 
developing steroid induced osteoporosis, were identified. Concomitant data about pre-
scription of drugs used for prevention and treatment of osteoporosis were obtained. Of 
these 964 patients, 351 (36%) were taking some form of anti-osteoporotic medication. 
Our computer program appeared to be an effective signalling system in identifying 
patients at risk for steroid induced osteoporosis. 
Chapter 6 describes the effects on bone mass and biochemical bone markers, in 33 
prospectively studied patients with chronic obstructive pulmonary disease treated during 
one year with 800 fig/day inhaled beclomethasone, 800 ~lg/day inhaled budesonide or not 
requiring steroids. Both inhaled corticosteroids decreased serum concentrations of the 
formation markers osteocalcin and carboxy terminal propeptide of type I collagen 
(PICP). The resorption marker cross-linked carboxy terminal telopeptide of type I colla-
gen (ICTP) increased significantly more in patients treated with beclomethasone com-
pared to those treated with budesonide. The decrease in bone mineral density (BMD) 
was more pronounced in patients treated with beclomethasone (1.1 % in the spine; l.7% 
in the hip; p < 0.05) compared to those treated with budesonide (0.6% in both spine and 
hip) or in the control group. Taken together, inhaled corticosteroids in the dosages used 
appeared to affect both biochemical markers of bone turnover and bone mineral density. 
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Chapter 7 describes the acute short-term effects on biochemical parameters of calcium 
and bone homeostasis in fourteen postmenopausal women treated with high dose of 
prednisone (60mg/day) alone or with additional etidronate. Before and during 5 days of 
treatment, serum calcium, phosphorus, creatinine, alkaline phosphatase activity, osteo-
calcin, carboxy terminal propeptide of type I procollagen (PICP), cross-linked carboxy 
terminal telopeptide of type I collagen (ICTP), PTH, 25 hydroxy vitamin D and urinary 
excretion of calcium over 24 hours were measured. Significant differences from baseline 
were found in osteocalcin and urinary excretion of calcium in both groups and for ICTP 
in only one group. Significant differences between groups were calculated at day 5 of the 
study for osteocalcin, ICTP and 24 hours of urine calcium excretion. In the group addi-
tionally treated with etidronate, osteocalcin increased and urinary calcium excretion and 
ICTP decreased. In the prednisone alone treated group, osteocalcin decreased and urinary 
calcium increased. 
Chapter 8 describes the results of a randomised clinical trial studying the preventive 
effects of etidronate on corticosteroid-induced bone loss in postmenopausal women with 
temporal arteritis treated with high dose of prednisone (mean dose I1mg/day). At 3, 6 
and 12 months, vertebral BMD was significantly (p < 0.01) increased in the etidronate 
treated group and decreased in the group without etidronate , based on mean actual and 
percent changes from baseline in BMD and mean changes from baseline in BMD Z-
score. Between-group comparisons were also significant (p < 0.002) at each time point. 
At 12 months, the mean percent change from baseline in BMD was + 1.42 ± 0.45% in the 
etidronate treated group and -4.95 ± 0.64% in the group without etidronate. Nine of the 
10 patients treated with etidronate and prednisone showed an increase in bone mass, 
whereas all 10 patients treated with only prednisone showed a decrease of BMD. 
At 12 months, the change from baseline in serum alkaline phosphatase was 6.2 ± 3.9% in 
the etidronate treated group and -5.3±3.0% in the group without etidronate (p< 0.05, 
between groups). No clinically significant changes in routine clinical and laboratory 
evaluations were noted. Etidronate was well tolerated, and no adverse events related to 
etidronate treatment were reported. 
Chapter 9 describes the results of a randomised clinical trial studying the effect of calci-
um supplementation and intermittent cyclic etidronate on BMD in patients with estab-
lished corticosteroid-induced osteoporosis. Patients who had established corticosteroid-
induced osteoporosis and received chronic prednisone therapy (> 10 mg/d) were enrolled 
in a prospective 12-month, open-label study. BMD of the spine (Ll-L4) and proximal 
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femur (total hip, femoral neck, trochanter, and Ward's triangle) was measured by DEXA, 
at baseline, 6 months, and 12 months. Serum calcium, phosphorus, and alkaline phos-
phatase were also measured. Serum calcium, phosphorus, and alkaline phosphatase lev-
els did not change significantly during the study in either treatment group. At baseline, 
women had significantly lower baseline BMD of the spine and proximal femur (total hip) 
and patients with pulmonary disease had significantly longer duration of prednisone ther-
apy and cumulative prednisone dose. It appeared that, intermittent cyclic etidronate 
reversed the progressive loss of bone mineral density of the spine and proximal femur in 
female and male patients with established osteoporosis secondary to chronic corticos-
teroid (prednisone) therapy for pulmonary and non-pulmonary diseases. Calcium supple-
mentation alone did not prevent or attenuate these corticosteroid-induced losses. 
In part V of this thesis the main findings and clinical implications are discussed and fur-
ther suggestions for research are given. 
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Osteoporose is een ernstige bijwerking van het gebruik van glucocorticoiden. De gevol-
gen van heup en wervel fracturen bei'nvloeden de kwaliteit van leven negatief. Een kwa-
liteit die al verminderd was ten gevolge van de oorspronkelijke ziekte waarvoor men glu-
cocorticoiden moest gaan gebruiken. Ook de kosten van de medische behandelingen en 
het verlies aan productiviteit zouden een uitdaging moeten zijn, voor medici, om niet 
alleen behandelopties te bedenken, maar ook om strategieen te ontwerpen waarbij actief 
naar juist dit soort patienten gezocht en gekeken kan worden zodat primaire preventie 
kan worden bedreven. 
De gevolgen van het gebruik van glucocorticoiden voor de botten en de consequenties 
voor de patient worden vaak onderschat of worden nauwelijks herkend door medici. 
Onderzoek door en bijscholing van artsen, zal moeten lei den tot een veilig vangnet voor 
degenen die niet zonder glucocorticoiden kunnen. Dit proefschrift bevat een compact 
overzicht over de pathofysiologie, behandeling en research van glucocorticoid-geindu-
ceerde osteoporose in het verleden, heden en toekomst . 
In hoofdstuk 1 wordt een overzicht gegeven van de verschillende pathofysiologische 
mechanismen betrokken bij het ontstaan van glucocorticoid-geinduceerde osteoporose. 
Hoofdstuk 2 beschrijft het fractuurrisico van patienten die met glucocorticoiden behan-
deld worden. Het bepalen van het risico is erg moeilijk, omdat het is opgebouwd uit ver-
schillende componenten die sams weI en soms ook niet met elkaar samenhangen. De 
verdeling in skelet gerelateerde en niet- skelet gerelateerde componenten lijkt een logi-
sche verdeling, echter de onderlinge afhankelijkheid van deze twee componenten, maakt 
het moeilijk om fractuurrisico te voorspellen. BMD speelt een belangrijke 1'01 in de skelet 
gerelateerde zijde van de kans op fracturen. De verschillen tussen de BMD-meetmetho-
den, impliceren een zorgvuldige interpretatie van onderzoek gegevens gezien de gevaren 
voor onder- en overschatting. Deze worden in dit hoofdstuk besproken. 
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Hoofdstuk 3 geeft een overzicht van de literatuur over inhalatie steroi'den en de effecten 
daarvan op de calcium- en botstofwisseling. De literatuur bIijkt onvolledig en is door de 
zeer vele factoren die van invloed zijn op het bot moeiIijk te interpreteren. In het alge-
meen kunnen we zeggen dat inhalatie stero'iden mindel' systemische bijwerkingen hebben 
dan orale toedienings vormen. Echter in hogere doseringen vormen ze nog steeds een 
risico op glucocorticoid-geinduceerde osteoporose. 
Hoofdsfuk 4 geeft een overzicht van de potentiele behandelingsvormen die voor gluco-
corticoid-geinduceerde osteoporose beschikbaar zijn. Het bIijkt dat er maar een combina-
tie is die daadwerkeIijk fractuurreductie heeft aangetoond; dat is de combinatie: vitamine 
D, calcium en bisfosfonaten. 
In hoofdstuk 5 worden de resultaten besproken van een screening van databases van 
apothekers m.b.v. een speciaal door ons ontwikkeld computerprogramma. Dit program-
ma stelt ons in staat om de patienten te selecteren die meer dan 7,5 mg prednison gebrui-
ken gedurende drie maanden of langer. We hebben 22 grote databases kunnen screenen 
die random over Nederland verspreid waren. De onderzochte populatie bestond uit 
248.169 mensen waarvan 157.461 personen ziekenfonds en 90.708 particulier verzekerd 
waren. Ook werden data verzameld over de andere medicatie van deze patienten en dan 
met name medicamenten die gebruikt kunnen worden in de behandeling van osteoporo-
se. De 1eeftijd specifieke prevalentie van langdurig, hoog corticosteroid gebruik kon wor-
den berekend uit de populatie die ziekenfonds verzekerd was. De prevalentie verschilde 
van 0.015% in de groep van 0-10 jaar tot 1.4% in de groep van 80-89. De overall preva-
lentie was 0.27%. Van de onderzochte totale populatie bleken er 964 personen te zijn die 
meer dan 7,5 mg prednison gebruikten gedurende drie maanden of langer (532 vrouwen 
en 432 mannen). Van deze groep bleken 351 personen (36%) enige vorm van anti-osteo-
porotische medicatie voorgeschreven te krijgen. 
Ons computerprogramma zou een effectief middel kunnen zijn om patienten te identifi-
ceren die een verhoogd risico hebben op glucocorticoid-geinduceerde osteoporose. 
Hoofdsfuk 6 bevat de resultaten van een prospectieve pilotstudy van 33 patienten met 
COPD behandeld met 800 flg beclomethason en budesonide per dag. De effecten van 
inhalatie steroi'den op BMD en de markers van calcium en botstofwisseling worden 
beschreven. Het blijkt dat osteocalcin en PICP verlaagd worden door het gebruik van 
inhalatie steroi'den. De marker die vooral de activiteit van osteoclasten aangeeft steeg 
significant meer in de groep die behandeld werd met beclomethason. Ook de BMD daal-
de in de met inhalatie steroi'den behandelde groep. Het meest uitgesproken was de daling 
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in de groep behandeld met beclomethason (l.1 % in de wervelkolom en 1.7% in de heup). 
Het blijkt dat inhalatie steroi'den zowel de BMD als de markers van calcium en botstof-
wisseling negatief bei'nvloeden. 
Hoofdstuk 7 beschrijft de resultaten van een studie over het acute effect van etidronaat 
op de parameters van calcium en botstofwisseling van veertien postmenopauzale vrou-
wen met arteritis temporalis die met hoge doses prednison behandeld worden. Gedurende 
vijf dagen werden serum calcium, fosfaat, creatinine, alkalische fosfatase, osteocalcin, 
PICP, ICTP, PTH, 25 hydroxy vitamine D en 24 uur urine calcium verzameld en geme-
ten. Significante veranderingen ten opzichte van de bas ale waarden, werden gevonden 
voor osteocalcin en urine calcium excretie in beide groepen en ICTP in een groep. Ver-
schillen tussen twee groepen werden berekend op dag vijf en waren significant voor oste-
ocalcin, ICTP en urine calcium excretie. In de groep die behandeld werd met etidronaat 
steeg de osteocalcin en daalde de urine calcium excretie en de ICTP. In de groep aan de 
behandeld met prednison zonder de toevoeging van etidronaat daalde de osteocalcin en 
steeg de urine calcium excretie. 
Hoofdstuk 8 beschrijft de resultaten van een prospectief gerandomiseerde klinische stu-
die betreffende het pre venti eve effect van etidronaat op de BMD van postmenopauzale 
vrouwen die vanwege arteritis temporalis starten met behandeling met hoge doses pred-
nison (gemiddelde dosis Ilmg/dag). In de groep die met etidronaat behandeld werd steeg 
de botmassa (+ 1,42%) en in de groep zonder etidronaat daalde de BMD (- 4,95%) signi-
ficant. Negen van de tien patienten behandeld met etidronaat toonden een stijging van de 
BMD terwijl bij aile patienten in de controle groep een BMD verlies werd gevonden. Na 
12 maanden veranderde het alkalische fosfatase in de behandelde groep met + 6, 2% en 
in de controle groep daalde de alkalische fosfatase met 5,3%. Er werden geen bijwerkin-
gen van de behandeling met etidronaat gemeld. 
Hoofdstul .. 9 beschrijft de resultaten van een prospectief gerandomiseerde klinische stu-
die betreffende het effect van etidronaat en calcium op reeds bestaande glucocorticoid-
geinduceerde osteoporose. Gedurende 12 maanden werden patienten gerekruteerd die 
chronisch meer dan 10 mg prednison per dag gebruikten. BMD van de heup en wervel-
kolom werden gemeten m.b.v. DEXA op tijdstip 0, 6 en 12 maanden. Serum calcium, 
fosfaat en alkalische fosfatase werden ook bepaald. Het bleek dat deze biochemische 
parameters gedurende de studie niet veranderden. Het bleek dat vrouwen een significant 
lagere BMD van de heup en de wervelkolom hadden. Tevens was opvallend, dat de 
patienten die glucocorticoiden gebruikten vanwege COPD, gedurende een langere tijd en 
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hogere dosering gebruikten dan de rest van de populatie. Het bleek dat etidronaat een 
positief effect had op de BMD van patienten met osteoporose ten gevolge van chronisch 
prednison gebruik ongeacht de indicatie. Calciumsupplementen konden verdere progres-
sie van botverlies niet voorkomen. 
In deel V van dit proefschrift worden de belangrijkste bevindingen besproken en in een 
klinisch perspectief geplaatst. Voorts worden aanbevelingen geformuleerd voor verder 
onderzoek. 
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Het schrijven van dit dankwoord vervult mij met ambivalente gedachtenkronkels. AIler-
eerst is het een opluchting om een dankwoord te kunnen schl'ijven omdat dit betekent dat 
het proefschrift afgerond is. Anderzijds behoort het dankwoord, samen met het curricu-
lum vitae, waarschijnlijk tot het meest gelezen gedeelte van een proefschrift, hetgeen 
eisen stelt aan de kwaliteit ervan. Degene die nu een prachtig epistel verwacht, raad ik nu 
af verdeI' te lezen. 
Het gezegde "Betel' laat dan nooit" is er weI een die opgaat voor dit proefschl'ift. Al met 
al is het een proefschl'ift "oude stijl" geworden, zeker gezien de manier waarop het tot 
stand gekomen is. Daarbij denk ik allereerst aan mijn "werkplek". Al in een zeer pril sta-
dium van de conceptie van dit proefschrift werd ik gedwongen te verhuizen van mijn 
werkkamer naar de hoek van de huiskamer in verb and met uitbreiding van het gezin. 
Deze plek had voor- en nadelen, al werden de nadelen pas in de laatste fase van de uit-
drijving van dit proefschrift pijnlijk duidelijk. 
Lieve Nellie, zander jouw persoonlijk motiverend vermogen en verzorgende eigenschap-
pen zou dit proefschrift er niet zijn gekomen. Ook het wegcijferen van jouw persoonlijke 
wens en en verlangens vanwege dit proefschrift, had niet veellanger moeten duren. Dank 
vool' je 'gedwongen' visites buitenshuis, zodat ik rustig kon werken; je fantastische plan-
ning waardoor de kinderen zo lang mogelijk op bed lagen of weg waren zodat ik in aIle 
rust kon werken. lk hoop me de komende tijd ook meer aan jouw planning te kunnen 
houden. Herbert, ik moest steeds aan je klaagzin denken: "Papa, het is niet eerlijk, u zit 
nu al weer achter de computer. U mag er de hele dag al achter zitten. Wanneer mag ik nu 
eens? Voorlopig aItijd, jongen!!! Al is het maar omdat ik een nieuwe computer heb moe-
ten kopen. 
Beste promotoren, ook voor jullie is dit een apart proefschrift geworden. Ton, bedankt 
voor het initieel vertrouwen, je inspanningen en bijna vaderlijke bemoedigingen in de 
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laatste fase van dit proefschrift. De waardering voor alles wat je hebt gedaan en de 
manier waarop is enorm. Huib, bewaker van kwaliteit, zo zal ik je zeker herinneren. 
Dankzij jou is het proefschrift geworden tot wat het nu is. Dank, dat je ondanks het feit 
dat je pas in een laat stadium betrokken raakte, je de moeite getrooste, het proefschrift 
nauwgezet te corrigeren en suggesties te geven, zodat het eindresultaat er mag zijn. In de 
gezamenlijke bespreek sessies heb ik veel geleerd over het hoe en waarom met betrek-
king tot research en het schrijven van artikelen. Beste promotoren, bedankt dat ik met 
jullie heb mogen samenwerken. De kennis die ik door jullie heb verkregen zal ik in de 
toekomst kunnen gebruiken en hopelijk verder uitbreiden. 
Beste Henk, een verlies voor het internistencorps. Onze eerste tijd in het Usselland zie-
kenhuis zal ik nooit vergeten. Samen met Sten begonnen aan onze eerste baan als arts-
assistent. Ik heb geluk gehad dat ik jou als supervisor trof. Je manier van opleiden was 
onopvallend en efficient. J e gaf me het idee dat ik de afdeling "run de" , hoe weI in feite jij 
dat deed. Echter het zelfvertrouwen en de ervaringen die ik in die tijd heb opgedaan zijn 
van vee I betekenis geweest voor mijn latere loopbaan. In die tijd kwam ik ook via jou 
voor het eerst in aanraking met osteoporose. Terloops werd opgemerkt:" Ik doe nog iets 
met osteoporose, hier heb je wat literatuur, als het je wat lijkt heb ik nog weI wat voor je 
te doen". Awel, dat heb ik geweten !! Ik heb er inderdaad am'dig wat werk aan over 
gehouden, letterlijk en figuurlijk. Ondanks mijn overgewicht en de samenwerking met 
jou, ben ik toch in opleiding gekomen tot internist, ben ik artikelen gaan publiceren en 
heb ik delen van de wereld gezien, die ik anders nooit zou hebben aanschouwd. Ook heb 
ik voordrachten kunnen geven en ben ik vertrouwd geraakt met de commerciele zijde 
van het medisch bedrijf en het klinisch geneesmiddelenonderzoek. 
Tevens ben jij de motor geweest achter de artikelen die van onze hand verschenen zijn. 
Je geduld met mij als het gaat over de snelheid, of beter gezegd traagheid, waarmee de 
artikelen geschreven werden, is opmerkelijk te noemen. Ook heb ik bewondering voor je 
onnavolgbare wijze van het documenteren en archiveren van de originele onderzoeksre-
sultaten. Al met al kun je dit proefschrift zeker ook zien als een soort tweede promotie 
voor jezelf. De meeste studies zijn opgezet zonder hulp van buitenaf, zowel in financiele 
als in intellectuele zin. Dit heeft geleid tot hypotheses en studies ontsproten uit de dage-
lijkse poliklinische praktijk; resulterend in kleine pilotstudy's met echter een aardige 
impact. Terugkijkend was de studie opzet niet altijd even mooi en compleet, maar we 
hebben het naast onze dagelijkse bezigheden weI voor elkaar gekregen. Beste Henk, jij 
bent nu een belangrijke directeur van een goed lopende site management organisatie, die 
de laatste jaren explosief gegroeid is. Ondanks dat, ben je echter nog steeds de Henk 
Mulder die ik ken van vroeger. Wat mij betreft is er een basis gelegd voor een samen-
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werking die ik graag in de toekomst zal voortzetten. 
Terugdenkend aan mijn eerste fase van de opleiding tot internist in het St. Clara zieken-
huis dank ik Albert, dat je al in een vroeg stadium de AMVB hebt willen doorvoeren. De 
daarllit volgende compensatie na diensten en de lagere werkdruk op de afdeling, hebben 
mij in staat gesteld in een traag doch gestaag tempo voort te gaan. Hoewel ik me mis-
schien tot vervelens toe sterk heb gemaakt voor de naleving van de regels, heeft de vrije 
tijd geleid tot het schrijven van wetenschappelijke artikelen, die jij ook meer dan eens 
kritisch hebt doorgelezen. Je adviezen betreffende onderzoek, commercialiseren van 
onderzoek en het aanvragen van patenten zijn in goede aarde gevallen. Je enthousiasme 
waarmee je je IC-idealen lIitdroeg hebben bijgedragen aan mijn keuze tot intensivist. Ik 
hoop in de toekomst onze samenwerking nog voort te zetten op het gebied van IC, 
research en commercie. 
Ook de bibliothecaresse van het Clara ben ik ontzettend dankbaar. In het Dijkzigt heb ik 
zelf moe ten ervaren hoeveel tijd het kost om artikelen op te zoeken, aan te vragen en te 
kopieren. Dankzij jou heb ik met een minimum aan tijd, de meest onmogelijke artikelen, 
uit de meest exotische tijdschriften kunnen krijgen. Deze hoeveelheid aan artikelen 
bewees zijn waarde tijdens het schrijven van de introductie. Zo'n bibliothecaresse is voor 
iedere arts, die naast zijn dagelijks werk ook nog onderzoek doet, onmisbaar. 
Nu ik het woord introductie heb laten vallen, denk ik direct aan mijn voorlaatste werkge-
vel's. De groep mensen die in het AZR de grootste moeite do en om een volwaardige IC 
opleiding te behouden, hebben mij stuk voor stuk de mogelijkheid gegeven om dit proef-
schrift af te ronden en in de huidige vorm te gieten. Met name professor Bruining en Djo 
Hasan en de groep ICP hartelijk dank. 
Sten, ik zal je missen nu je vertrokken bent naar warmere oOl'den in het zuiden van 
Frankrijk. Het lijkt weI een vakantie adres. Ik weet weI betel'. Bedankt voor de vriend-
schap, collegialiteit en goede tijd die we samen gehad hebben. Ook hebben we veer 101 
gehad in het schrijven van de artikelen. 
Onno en Michiel, dank voor de introductie in jullie apothekerswereld, die geleid heeft tot 
een wederzijdse vruchtbare samenwerking. 
Joop, bedankt voor de "mooie" plaatjes van de botten en je ondersteunende 1'01 in het 
voItooien van dit proefschrift. 
Ook al mijn collegae vanuit de Clara, waaronder Arthur, Ernst-Jan, Sten, Henriette, 
Peter, Ron, Cees en degene die ik natuurlijk weer vergeet, nog bedankt. Peter, jouw pro-
motie komt nog. Met plezier zal ik ook de fouten in jouw proefschrift opsporen, zoals jij 
dat ook bij mij hebt gedaan. 
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Jan en Andre, van je schoonfamilie moet je het maar hebben. Hartelijk dank voor de 
energie die jullie hebben gestopt in het opnieuw maken van de grafieken en tab ellen die 
door het failliet gaan van het Ave waren verdwenen. Jullie hulp was onmisbaar. 
Verder wi! ik een ieder bedanken die zijn of haar bijdrage heeft geleverd en die ik niet bij 
name heb genoemd. Het is geen onwi! of desinteresse maar onmogelijk om een ieder die 
een bijdrage heeft geleverd persoonlijk te noemen en te bedanken. 
Nellie, het proefschrift is klaar, ik ben internist, intensivist en nog steeds met je getrouwd. 
Ik hoop hiervan nog lang te kunnen genieten. Zo, en nu een; nee geen Bavaria!, eerst 
afvallen. 
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CURRICULUM VITAE 
De auteur werd geboren op 8 augustus 1965 te Vlaardingen. In 1984 behaalde hij het 
VWO diploma aan de scholengemeenschap "Guido de Bres" te Rotterdam. In datzelfde 
jaar begon hij met de studie geneeskunde aan de Erasmus Universiteit te Rotterdam. In 
1991 behaalde hij het artsexamen. Dam'na is hij AGNIO interne geneeskunde geweest in 
achtereenvolgens het IIsseliand Ziekenhuis, AZR "Dijkzigt" en het St. Clara Ziekenhuis. 
Op 1 april 1993 begon hij zijn opleiding tot internist op de afdeling interne geneeskunde 
van het St. Clara Ziekenhuis te Rotterdam (opleider: dr. A.F. Grootendorst). Op 1 sep-
tember 1997 werd de opleiding voortgezet in het AZR "Dijkzigt" (opleider : Prof. dr. 
M.A.D.R. Schalekamp). Op 1 april 1999 werd hij ingeschreven in het specialistenregis-
tel'. Gedurende het laatste jaar van de opleiding tot internist heeft hij de opleiding tot 
internist-intensivist gevolgd op de verschillende I.e. afdelingen van het AZR "Dijkzigt". 
Op 1 september 1999 werd hij geregistreerd als sub specialist. Vanaf 1 september is hij 
als staflid verbonden aan de afdeling intensive care Thoraxchirurgie van het AZR "Dijk-
zigt". Ret onderzoek dat heeft geleid tot dit proefschrift werd uitgevoerd in het IIsseliand 
Ziekenhuis en het AZR "Dijkzigt". Tevens is hij oprichter van de DRCO en de EMCR-
IC waarvan hij tevens voorzitter is. 
LIST OF ABBREVIATIONS 
DXA=Dual energy X-ray Absorptiometry 
BMD=Bone Mineral Density 
SD=Standard Deviation 
WHO=World Health Organisation 
IGF=Insulin-like Growth Factor 
PTH=Parathyroid Hormone 
BMU=Basic Multi-cellular Units 
BRU=Bone Remodelling Units 
Ca=Calcium 
25-(OH)D3=25 hydroxyvitamin D 
1,25-(OHhD3=1,25 dihydroxyvitamin D 
LH=Luteneizing Hormone 
LHRH=Luteneizing Hormone-Releasing Hormone 
ACTH=Adrenal CorticoTrophin Hormone 
FSH=Follic1e Stimulating Hormone 
DHEA=DiHydroxyEpiAndrosterone 
GC=GlucoCorticoid 
QCT=Quantative Computer Tomography 
FEA=Finite Element Analysis 
HP A=Hypothalamic-Pituitary-Adrenal 
Bec1o=Beclomethasone 
B udeso=B udesonide 
PICP=carboxy terminal propeptide of type I procollagen 
ICTP=cross-linked carboxy terminal telopeptide of type I collagen 
N=Number of participants 
GE=Gastro-Enteral 
BMI=Body Mass Index 
SP A=Single Photon Absorptiometry 
DP A=Dual Photon Absorptiometry 
R'=medication 
RA=Rheumatoid Arthritis 
IM=Intra-Muscular 
P=Prospective 
R=Randomised 
C=Controlled 
PIC=Placebo Controlled 
DB=Double Blind 
PMR=Polymyalgia Rheumatica 
SLE=Systemic Lupus 
PMP=Postmenopausal 
HRT=Hormone Replacement Therapy 
